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ABSTRACT 
 
In normal development, cells from the totipotent zygote give rise to the pluripotent inner cell 
mass and epiblast cells, which subsequently become more and more restricted, and ultimately, 
originate all the differentiated cells of the human body. In this Master thesis a chemically 
defined protocol based on signalling present in vivo was used to differentiate in vitro a human 
embryonic stem cell (hESCs) line, with the intent of recapitulating cardiac development. 
Along the differentiation protocol, the role of CCBE1 (Collagen and Calcium-Binding EGF-like 
domain 1) was studied. CCBE1 is a growth factor which has already been reported in mouse as 
being expressed and potentially required for the generation of cardiac precursor cells. As such, 
this study focused on three main topics: the characterization, function and regulation of CCBE1 
in hES cells.  
Regarding characterization, CCBE1 shows an expression pattern similar to the one previously 
reported in mouse ES cells, i.e. it is highly expressed in pluripotency, when cells start to 
differentiate it is downregulated, and its mRNA and protein levels rise progressively as cells 
differentiate towards cardiac precursors. There is a strong association between mRNA and 
protein expressions, as determined by quantitative PCR analysis and immunocytochemistry 
assays. 
As for CCBE1 function, this was assessed by knocking down (KD) CCBE1 in hESCs using shRNA. 
CCBE1 KD cells lost their ability to differentiate properly into cardiac precursors, as evidenced 
by the downregulation of cardiac precursors genes. Additionally, pluripotency markers genes 
were also deregulated upon CCBE1 KD. 
The pattern of CCBE1 expression raised some questions about its regulation in pluripotency 
and cardiac precursor cells. To investigate this, Chromatin Immunoprecipitation (ChIP) assays 
were performed with an antibody against a pluripotency protein (NANOG), one against an 
early mesoderm protein (BRACHYURY), and one against a cardiac protein (ISL1). The results 
revealed binding of NANOG, BRA and ISL1 to distinct CCBE1 regulatory regions and at different 
differentiation timings.     
This work contributed to a further understanding of the complex process of human heart 
development by studying CCBE1, which is required for differentiation of cardiac mesoderm 
precursors. 
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RESUMO 
 
O estudo da biologia do desenvolvimento, tema central desta dissertação, estende-se desde o 
momento da fecundação até à completa constituição do organismo adulto. 
A formação dos diferentes tecidos e órgãos, dos mais simples aos mais complexos, implica a 
ocorrência de diversos comportamentos celulares, tais como, divisão, crescimento, 
diferenciação, migração, adesão, arranjo espacial e apoptose.  
No que toca ao desenvolvimento dos vertebrados, e em particular do homem, o primeiro 
órgão a estabelecer-se, pelas três semanas de gestação, é aquele que tem como função 
distribuir oxigénio e nutrientes a todas as partes do organismo, o coração. 
As células mesodérmicas precursoras cardíacas, que detêm o potencial para gerar todos os 
tipos celulares que constituem o coração, são originadas durante a gastrulação, o primeiro 
processo embrionário de remodelação celular a partir do qual são originados os três folhetos 
germinativos, endoderme, mesoderme e ectoderme. O desenvolvimento do coração pode ser 
dividido em quatro etapas principais: formação do crescente cardíaco, no qual as células 
mesodérmicas se organizam em forma de crescente na região anterior do embrião; formação 
do coração linear, resultado do movimento ventral desempenhado pelas células precursoras; 
looping cardíaco, que consiste na reestruturação da forma linear do coração, desenhando um 
movimento em espiral; por fim, dá-se a remodelação do coração, em que por septação, se 
originam as aurículas e ventrículos. 
Muito do que se sabe sobre o desenvolvimento cardíaco resulta principalmente de 
investigação realizada recorrendo ao uso em animais modelo, particularmente galinha e 
ratinho. No entanto, existem diferenças genéticas e de desenvolvimento que distinguem o 
homem das referidas espécies. Deste modo, as células estaminais embrionárias humanas, 
obtidas a partir de embriões excendentários, resultantes de tratamento de fertilização in vitro, 
são um óptimo modelo para o estudo do desenvolvimento, fisiologia e doenças cardíacos. 
As células estaminais embrionárias derivam de embriões em estados de desenvolvimento 
muito precoces (morula ou blastocisto), são caracterizadas por terem o mesmo padrão 
genético que o daquelas que lhes deram origem, possuindo elevados níveis de expressão de 
OCT4, SOX2 e NANOG, a tríade que assegura o seu estado pluripotente. A pluripotência é 
definida como a capacidade detida por células individuais de se multiplicarem indefinidamente 
para originar outra célula pluripotente ou, em resposta a sinais provenientes do embrião (in 
vivo) ou da cultura celular (in vitro), se dividirem para originar todos os precursores celulares, 
que mais tarde originarão todos os tecidos do animal adulto. 
A especificação das células precursoras cardíacas a partir das células pluripotentes é realizada 
essencialmente pela acção sinérgica de dois factores parácrinos, BMP (Bone Morphogenetic 
Protein) e FGF (Fibroblast Growth Factor). 
Ainda que muitas questões acerca do desenvolvimento do coração já tenham sido 
respondidas, muitas outras persistem. Na tentativa de diminuir esta diferença, foi 
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desenvolvido um estudo focado na função de um factor de crescimento, já descrito em ratinho 
como importante na especificação cardíaca, ao longo da diferenciação de precursores 
cardíacos a partir de células embrionárias estaminais humanas. 
Este factor de crescimento, designado por Ccbe1, foi identificado num screening genético 
realizado em galinha. CCBE1 deve o seu nome aos diferentes domínios que o constituem, 
sendo eles, domínio de ligação a colagénio e cálcio e a um receptor membranar do tipo EGF 
(Epitelial Growth Factor).  
Reconhecendo o potencial, ainda pouco explorado, deste factor no desenvolvimento cardíaco 
precoce e das células estaminais como modelo experimental, foi desenhado um estudo que 
abordou essencialmente três vertentes; caracterização da expressão genética e proteica, 
função ao longo da diferenciação celular e regulação da expressão de CCBE1 por factores de 
transcrição já descritos. 
As células estaminais humanas utilizadas neste trabalho foram isoladas em 1998 e pertencem 
à linha celular H9. Foram cultivadas em meio que favorece a pluripotência e diferenciadas em 
precursores cardíacos num meio quimicamente definido suplementado com FGF2 e BMP4. 
Através de métodos de quantificação de mRNA (qPCR) e proteína (imunocitoquimica), foi 
descrito um padrão que sugere que CCBE1 desempenha uma função não apenas no processo 
de diferenciação cardíaca, mas também na manutenção da pluripotência, uma vez que tanto o 
transcrito como o produto proteico são grandemente expressos em células pluripotentes e 
precursores cardíacos. 
No que toca ao estudo da função, foram geradas duas linhas knock down usando um vector 
que contém um shRNA, afectando a expressão de CCBE1 em cerca de 70%. Estas células foram 
usadas em ensaios de diferenciação celular, tendo sido medidos os níveis de mRNA dos genes 
com expressão característica de precursores cardíacos, tais como NKX2.5, BRA, GATA4, KDR. 
Os resultados mostram que a expressão desses genes é afectada, sendo negativamente 
regulados quando a expressão de CCBE1 é reduzida. Portanto, CCBE1 regula positivamente a 
diferenciação em precursores mesodérmicos cardíacos, comprometendo a sua eficiente 
especificação quando não está presente nos níveis fisiológicos. Além destas análises realizadas 
no contexto de diferenciação celular, foram também medidos os níveis de expressão de genes 
particularmente transcritos em pluripotência, nomeadamente, NANOG, OCT4 e SOX2. 
Também a expressão destes genes foi afectada, positivamente, para NANOG e OCT4, e 
negativamente em relação a SOX2. 
De forma a explicar em termos de regulação ao nível do ADN o padrão de expressão 
apresentado por CCBE1, foram realizados diversos ensaios de imunoprecipitação da cromatina 
(ChIP). Por existir uma relação inversa entre o padrão de expressão de CCBE1 e BRA, colocou-
se a hipótese do segundo ter algum efeito na regulação do primeiro. Uma base de dados de 
ChIP-seq (ChIP e sequenciação) revelou que há ligação de BRA a CCBE1 após 36h de 
diferenciação na linhagem cardíaca. Por não ser conhecida acção repressiva de BRA, a hipótese 
formulada propunha que BRA teria uma acção indutora sobre CCBE1, quando na presença de 
um co-activador. Deste modo, os factores de transcrição escolhidos para a realização de ChIP 
foram BRA, NANOG e ISL1. 
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Os resultados de ChIP revelam que há ligação de BRA e NANOG em pluripotência e ligação de 
BRA juntamente com ISL1 em células precursoras cardíacas. A ligação destes hipotéticos 
dímeros é feita em regiões reguladoras distintas, de acordo com o contexto celular. Com o 
objectivo de complementar este resultado, linhas knock down de BRA e ISL1 foram geradas. Os 
níveis de transcrição de CCBE1 nas células com expressão de BRA reduzida suportam a 
hipótese colocada, de que BRA terá um efeito indutor sobre CCBE1. No entanto, o mesmo não 
pode ser afirmado no caso de ISL1, já que não há alteração da expressão de CCBE1 em células 
knock down para aquele factor de transcrição. Por conseguinte, é necessário testar o efeito 
activador sobre CCBE1 de outros factores de transcrição que possuam uma função importante 
na caracterização de precursores cardíacos. 
Concluindo, ficou provado pelos dados preliminares aqui apresentados que CCBE1 
desempenha uma função essencial no processo de diferenciação cardíaca, nos seus estádios 
mais primários, assim como na manutenção do equilíbrio da pluripotência.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. INTRODUCTION 
 
1.1. Developmental Biology of the Heart 
One of the most basic questions in developmental biology is how multicellular organisms 
develop from a single cell. During embryonic development, the egg is divided to give rise to 
many millions of cells that form structures such complex and varied as eyes, kidneys, heart or 
brain. 
The first scientific approach to explain the process of development was introduced by 
Hippocrates in the fifth century BC. His thesis explained this process in terms of physical 
principles of heat and moisture. 
Later on, another Greek philosopher named Aristoteles proposed two theories about 
development: pre-formation and epigenesis, but only the last one would be supported by the 
cellular theory developed by Mathias Schleiden and Theodor Schwann, in 1839 
During the twentieth century, another concept was introduced to the developmental biology 
discipline, the genetics. It was proposed that genes control cell behaviour by regulating where 
and when proteins are synthesized, and thus together with the environmental signalling 
determine the main processes involved in development, namely, cell division, pattern 
formation, morphogenesis, cell differentiation, migration, death and growth.  
This concept has been developed and further studied and it is now considered the basis of 
developmental biology research. Thousands of genes control the development of animals and 
a full understanding of the processes involved is far from being achieved. This Master’s Thesis 
is an attempt to take a little step towards the full understanding of the development process 
and focuses, particularly in the development of the heart, studying the role of a gene in this 
complex and multistep process.  
The heart is derived from the mesoderm, one of the three germ layers formed during 
gastrulation.  
In mammalians, after fertilization, the initiating step in development, the egg goes through 
several mitotic divisions, a process called cleavage, giving rise to the morula, and later to the 
blastocyst (Fig.1.1.1). The morula cells are capable of forming all the embryonic and 
extraembryonic structures of the body and are thus said to be totipotent (Gilbert, 2003; Geens 
et al., 2009). The blastocyst is composed of inner and outer cells; the inner cells are 
denominated the inner cell mass (ICM) and these cells can generate any cell type of the body. 
As such, these cells are no longer totipotent and are said to be pluripotent. (Fig. 1.1.2). 
Due to its potential, pluripotent cells from the ICM are largely used in developmental biology 
research. These cells can be removed from the embryo in a manner that lets them retain their 
pluripotent characteristics, and thenceforth they are called embryonic stem cells (Zhang et al. 
2006). This is an important topic that will be further discussed. 
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During the developmental process, the totipotent morula divides asymmetrically to form the 
blastocyst, which is composed of extraembryonic outer cells called trophoblast cells and the 
cells of the ICM. Once the blastocoel is formed, the resulting structure is called blastocyst. 
After the blastocyst is bound to the uterus, the first segregation of cells within the ICM begins. 
This rearrangement will give rise to two layers; the hypoblast (the lower layer) and the epiblast 
(the upper layer).  
 
 
 
 
 
  
 
Fig. 1.1.2 – Derivation of tissues in human embryo (adapted from Gilbert, 2003). 
Fig. 1.1.1 – Human 
embryo, 7 days of 
gestation. Blastocyst, 
immediately prior to 
gastrulation, 
composed by the 
epiblast, hypoblast, 
trophoblast and 
blastocoel (adapted 
from Gilbert, 2003). 
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Then, epiblast and hypoblast cells are reorganized, through a process called gastrulation, 
leading to the formation of the three germs layers: endoderm, mesoderm and ectoderm. Each 
of these layers constitutes the group of primary progenitors that will give rise to all tissues and 
organs of the embryo. This highly organised process of cell movement involves the whole 
embryo and it is first denoted by the formation of the Hensen’s Node and the Primitive Streak 
(Gilbert, 2003; Keller, 2005; Ohta et al. 2010; Yang et al., 2002).  
The primitive streak and the Hensen’s node are transitory structures through which cells 
migrate, formed by accumulation followed by thickening of epiblast cells at the posterior 
region of the embryo. The primitive streak appears as a depression in the midline of the 
epiblast and the node is a regional thickening of cells at the anterior end of the streak. The 
primitive streak defines the axes of the embryo. It extends from posterior to anterior sides, 
separating the left to the right portion of the embryo (Gilbert, 2003; Keller, 2005; Ohta et al. 
2010; Yang et al., 2002).  
When the streak is reaching half-maximal extension, epiblast cells in the streak undergo an 
epithelial to mesenchymal transition (EMT) and start to move as individual cells into the space 
between the epiblast and the hypoblast to form mesoderm as well as definitive endoderm. As 
gastrulation progresses, the primitive streak elongates distally, with a continuously ingression 
of cells. Eventually, while cells of the anterior portion of the embryo are undergoing 
gastrulation, cells at the posterior end are already starting to form organs. Consequently the 
embryo exhibits a posterior-to-anterior gradient of development. At the end of gastrulation, all 
the endoderm and mesoderm cells have moved inwards and the remaining epiblast gives rise 
to the third germ layer, named ectoderm. (Lawson and Pedersen, 1991; Keller, 2005; Ohta et 
al. 2010; Yang et al., 2002). The three germ layers are the genesis for distinct parts of the body: 
the endoderm cells generating the foregut, liver and pharinge; the mesoderm cells giving rise 
to the kidneys, muscles, heart, skeleton and blood and lastly, the ectoderm forming the 
nervous system and the skin (Wolpert, 2007). 
For the purpose of this work, the several steps of heart development, starting from mesoderm 
specification, will further be detailed bellow. 
After migrating through the primitive streak, the mesoderm cells are arranged in a 
mediolateral axis by a BMP gradient (Gilbert, 2003, Tonegawa et al., 1997). This different 
concentrations of BMP lead to the formation of different types of mesoderm, namely, the 
precordal plate, chordamesoderm, paraxial, intermediate and lateral plate (Fig. 1.1.3) (Gilbert, 
2003).  
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The precordal plate mesoderm is located more anteriorly and forms much of the connective 
tissues and musculature of the face (Wolpert, 2007).  
The chordomesoderm, which is positionated right in the middle of the embryo, establishes the 
anterior-posterior body axis and induces the formation of the neural tube, giving rise to the 
notochord at the future dorsal side of the embryo (Wolpert, 2007). 
The paraxial mesoderm, also called somatic dorsal mesoderm, forms the somites, which 
produce the cartilage of the vertebrae and ribs, the muscle of the rib cage, limbs, abdominal 
wall, back and tongue, and the dermis of the dorsal skin (Wolpert, 2007).  
The urogenital system has origin in the intermediate mesoderm (Wolpert, 2007). 
Finally, with higher levels of BMP expression there is the lateral plate mesoderm, which once 
again is subdivided in three mesoderm types: splanchnic, somatic and extraembryonic. It is the 
splanchnic mesoderm with a more ventral position that gives rise to the heart, blood vessels 
and blood cells of the circulatory system. The somatic and extraembryonic mesoderms form 
the lining of the body cavities and extraembryonic membranes important for transporting 
nutrients to the embryo, respectively (Gilbert, 2003).   
In vertebrates, the cardiogenic mesoderm arises from the anterior splanchnic lateral plate 
mesoderm. As mesodermal cells migrate through the streak to originate the presumptive heart 
mesoderm, they form two groups of cells at either sides of the Hensen’s node (Redkar et al., 
2001). These two clusters take a lateral migratory path towards the cranio-lateral part of the 
embryo to form the cardiac crescent, which begins to express cardiac transcription factors 
(Harvey, 2002) (Fig. 1.1.4). This structure contains the precursors of the endothelial lining of 
the heart, cushions cells of the valves, atrial and ventricular myocytes, and Purkinje fiber 
(Gilbert, 2003) (Fig. 1.1.5).   
 
Fig. 1.1.3 – The major lineages of amniote mesoderm: intermediate, chorda, 
paraxial and lateral plate mesoderm. Precordal mesoderm is not represented 
because it is presented in a more anterior region (adapted from Gilbert, 2003). 
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At the primitive streak stage there are transcription factors expressed transiently, such as 
Mesp1 and Mesp2 (mesoderm posterior 1 and 2) and Bra (Brachyury) and which are required 
for the movement of cells towards the anterior region of the embryo (Buckingham et al., 
2005). 
Once in contact with the endoderm, specification of the cardiogenic mesoderm is induced 
through the BMP (bone morphogenic protein) and FGF (fibroblast growth factor) signaling 
pathways, which are produced by that ventral layer. BMP stimulates heart or blood 
development depending on its interaction with the Wnt pathway. When in presence of Wnt 
proteins at posterior region of the embryo, BMP promotes blood and inhibits heart formation. 
On the other hand, Wnt inhibitors, such as Cerberus, Dickkopf and Crescent, together with 
BMPs, both produced by the anterior endoderm, promote heart formation (Fig. 1.1.5). At the 
anterior region, Wnt and BMP signaling promote head formation (Harvey, 2002). Moreover, it 
is known that BMP also induces Fgf8 synthesis in the endoderm (Alsan and Schultheiss, 2002), 
which appears to be an inducer of the expression of cardiac proteins, including Gata4, Gata5, 
Gata6, NKX2.5 (NK2 transcription-factor related, locus 5), Mef2b and Mef2c (myocyte 
enhancer factor), Hand1 and Hand2 (heart and neural crest derivatives expressed transcript 1 
and 2), Tbx5 (T-box 5) (Harvey, 2002 and Buckingham et al., 2005). It is known as well, that 
BMP might also act in a concentration-dependent manner to induce or repress cardiogenisis 
(Alsan and Schultheiss, 2002). Working together, these transcription factors activate the 
expression of genes encoding cardiac muscle-specific proteins, such as cardiac actin, ANF 
(atrial natriuretic factor) and α-MHC (α-myosin heavy chains).  
Fig. 1.1.4 – Heart development of the mouse. a) Cardiac progenitor cells originate in the primitive 
streak (PS), from where they migrate to the anterior region of the embryo at about embryonic day 
E6.5. b) In most vertebrates, the heart progenitor cells lie adjacent to the progenitors of the head 
(HF – head folds) and form the cardiac crescent, where differentiated myocardial cells are now 
observed (E7.5). c) The early cardiac tube forms through fusion of the cardiac crescent at the 
midline (ML) (E8). d) It subsequently undergoes looping (E8.5). e) By E10.5 the heart has acquired 
well-defined chambers, but is still a tube (upper panel, ventral view; lower panel, dorsal view). f) In 
the fetal heart (E14.5) the chambers are now separated as a result of septation and are connected 
to the pulmonary trunk (PT) and aorta (Ao), which ensure the separate pulmonary and systemic 
circulation of the blood, respectively, after birth.  
Anterior (A)–posterior (P) and right (R)–left (L) axes are indicated. Right atrium (RA), right ventricle 
(RV), left atrium (LA), left ventricle (LV), AA (aortic arch), AVC (atrioventricular canal), IFT (inflow 
tract), IVC (inferior vena cava), IVS (interventricular septum), OFT (outflow tract), PLA (primitive 
left atrium), PRA (primitive right atrium), PV (pulmonary vein), SVC (superior vena cava), Tr 
(trabeculae) (from Buckingham et al., 2005). 
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Once the cardiac crescent zone has been established, two cardiac progenitors regions can be 
distinguish, heart mesoderm ventrally and pericardial mesoderm dorsally, which are separated 
by the coelomic cavity. Heart mesoderm goes through another splitting that originates the 
muscular layer of the heart (myocardium) and the endocardium, whose cells originate the 
lining of blood vessels, heart valves, secrete the proteins that regulate myocardial growth and 
regulate the placement of nervous tissue in the heart (Gilbert, 2003). The pericardial 
mesoderm originates the pro-epicardial organ, from which the outer layer of the heart 
(epicardium), the coronary circulation and the interstitial fibroblasts are derived (Harvey, 
2002). 
The next step in heart development is the migration of the cardiac progenitor cells ventrally     
for the formation of the linear heart tube, in the midline of the embryo. While the fusion 
elapses, pulsations of the heart start being performed by the myocardial cells that develop 
their own ability to contract. Later, the linear heart tube acquires a spiral shape in 
consequence of a looping movement, in which its outer surface sweeps rightwards (Harvey, 
2002). Looping of the heart converts the original anterior-posterior polarity of the heart tube 
into the right-left polarity seen in the adult organism.  
While the heart is going through the looping, another morphological modification is taking 
place in its interior, the septation. Firstly, the heart is divided into one ventricle and one atrium 
by the endocardial cushions, which are structures composed by cells derived from the 
endocardium. The endocardial cushions are the precursors of the tricuspid and mitral valves, 
and aortic and pulmonary valves. Together with these endocardial cells, neural crest cells 
(migratory cell population that arises at the embryonic neural plate) also contribute for this 
septation (Gilbert, 2003). Another important function of the endocardial cushion is its 
participation in the formation of the right and left atrioventricular channels. From the bottom 
of the ventricle and the top of the atrium, inter-ventricular and inter-atrial septae are formed, 
respectively. Muscular cells from these septae start to proliferate and eventually fuse with the, 
already cited, endocardial cushions, therefore giving rise to a four-chambered heart (Gilbert, 
2003; Harvey, 2002).   
Going back in the developmental time line, it is import to point that there are two sources of 
myocardial cells for the building of the mammalian heart (Buckingham et al., 2005; Musunuru 
et al. 2010), which will contribute to different parts of the heart. These distinct cells sources 
Fig. 1.1.5 – Signaling pathways implicated into cardiogenic induction. Inductive interaction 
involving Wnt and BMP signalling enables the generation of heart and blood lineages from the 
lateral plate mesoderm (adapted from Gilbert, 2003). 
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are organized into two fields, which are morphoregulatory and dynamic regions of 
developmental potency for the formation of the heart (Harvey, 2002) (Fig. 1.1.6). They are 
identified at the crescent cardiac stage as the first heart field (FHF) (more ventrally) and 
secondary heart field (SHF) (more dorsally). Gene markers such as Nkx2.5, Tbx5 and Hand1 are 
expressed in the first heart field that contributes to the formation of both the atria and the 
ventricles. On the other hand, the secondary heart field is characterized by the expression of 
Nkx2.5, Fgf10 (fibroblast growth factor 10), Isl1 (insulin gene enhancer protein 1), Hand1 and 
Hand2, and its descendent cells will populate the right ventricle and both atria (Buckingham et 
al., 2005).     
 
 
 
 
Throughout the developmental process, the heart must maintain its rhythmical contractions, 
since their appearance during heart tube formation, through coordinated activation of the 
myocardium. These rhythmical contractions are carried out by the cardiac conduction system 
(CCS), which is composed by sinoatrial (SA) node, the atrioventricular (AV) node and a group of 
conducting fibers. (Boullin and Morgan et al., 2005).  
SA node is the first element to function in the CCS, it is found next to the wall of the right 
atrium, working as the dominant pacemaker, once its cells have the most rapid inherent 
rhythm. After, it passes the impulse to the AV node via the atrial myocardium.  
When formed, the AV node delays the impulses passage from atria to ventricular myocardium. 
The conduction pathway, which ends with the Purkinje fibers, spreads the electric signal by the 
all heart.  
The nodal cells of the AV and SA nodes are similar to embryonic cardiomyocytes, nevertheless 
they are small with a poorly developed sarcoplasmic reticulum and lack a functional contractile 
unit due to poorly organized actin and myosin filaments. 
The formation of the heart is a complex morphogenetic process that depends on the 
spatiotemporally regulated contribution of cardiac progenitor cells. These mainly derive from 
the splanchnic mesoderm of the first and second heart field (SHF), with an additional 
contribution of neurectodermally derived neural crest cells that are critical for the maturation 
of the arterial pole of the heart (Vincent and Buckingham, 2010). All together, this 
Fig. 1.1.6 – Cardiac crescent organization in the mouse embryo. The location and contribution of 
the second heart field (green), and is compared with the myocardial cells that are derived from 
the first heart field (red). Frontal views are shown for embryonic day 7.5 (E7.5) and E10.5, and 
lateral views for stages E8 and E8.5. LA (left atria), LV (left ventricle), OFT (outflow tract), PhA 
(pharyngeal arches), RA (right atrium), RV (right ventricle) (from Buckingham et al., 2005). 
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developmental process culminates in the formation of the “sun” of the body, as William 
Harvey described the heart in the seventieth century. 
 
 
1.2. Cell-Cell Communication in Development 
A body is more than a collection of randomly distributed cell types. Development involves not 
only the differentiation of cells, but also their organization into multicellular arrangements 
such as tissues and organs. Many of the answers to questions about morphogenesis involve 
the properties of the cell surface. Each cell type has different sets of proteins at its surface, and 
some of these proteins are responsible for forming the structure of the tissues and organs 
during development. 
The extracellular matrix (ECM) appears as a critical region for much of animal development. It 
is composed by macromolecules secreted by cells into their immediate environment and it is a 
source of developmental signals. Cell adhesion and cell migration, essential behaviors on the 
developmental process, depend on the ability of cells to form attachments to extracellular 
matrices. ECM molecules can interact with their receptors on the plasma membrane triggering 
a cascade of events such as changes in gene expression, which in turn induces changes in cell’ 
behavior.  
Extracellular matrices are made up of collagen, proteoglycans and glycoproteins, such as 
fibronectin and laminin. Fibronectin, for example, plays an important role in heart cell 
precursors’ migration to the midline and, when its signaling is interrupted, heart-forming cells 
fail to fuse and two separate hearts develop (Gilbert, 2003). Flectin is another protein of the 
extracellular matrix involved in heart development, particularly in the looping. When chick 
embryos are treated with monoclonal antibodies against flectin, heart looping is randomized 
(Brand, 2003). 
One of the most important receptors that allows extracellular matrix to transduce its signal to 
the cell is the integrin. It binds to fibronectin on the outside of the cell and on the inside of the 
cell it serves as an anchorage site for actin microfilaments, which provide cell movement.  
Another important mechanism of cellular communication uses paracrine factors. When 
proteins synthesized by one cell can diffuse over the ECM to induce changes in neighboring 
cells, the event is called a paracrine interaction, and the diffusible proteins are called paracrine 
factors. Many of these factors can be grouped into four major families on the basis of their 
structure, and all of them are somehow involved in heart development. These families are 
fibroblast growth factor (FGF), transforming growth factor β (TGF-β), Hedgehog and Wingless 
(Wnt) (Gilbert, 2003). 
 The FGF family has about two dozen structurally related members and is associated with 
several developmental functions, including angiogenesis and mesoderm formation (FGF2), and 
axon formation. FGFs can activate, by fosforilation, a set of receptor tyrosine kinases called the 
fibroblast growth factor receptors, which in turn can activate, namely, Ras/MEK/ERK signal 
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transduction pathway and modulate the expression of, for example, serum response factor 
transcription factor, which enhances transcriptional activity of cardiac differentiation genes. 
(Alsan and Schultheiss, 2002; Brand, 2003; Gilbert, 2003).  
The TGF-β superfamily comprises the TGF-β family, the activin family, the bone morphogenetic 
proteins (BMPs), the Vg1 family, glial-derived neurotrophic factor and the Mullerian inhibitory 
factor.  From all these molecules, the one that plays an important role in heart development is 
the BMP, as described above, particularly BMP4, which has been found to regulate cell 
division, apoptosis, cell migration and differentiation. Members of this family bind to a TGF-β 
receptor dimer (type II and type I), which, when activated, can phosphorilate the Smad 
proteins 1 and 5 that, together with the Smad 4, are translocated to the nucleus to regulate 
gene expression (Gilbert, 2003).   
BMP positively regulates FGF expression and, together their signals cooperate during cardiac 
induction. The FGF8 knockout mouse develops aberrantly and exhibits left–right asymmetry 
and various other cardiac malformations. However, early heart formation is not affected in this 
mutant mouse. In posterior mesoderm explants, a combination of BMP2 and FGF4 can 
stimulate heart formation, while neither factor alone can do so. Thus, FGF and BMP signaling 
seem to synergize to drive mesodermal cells into myocardial differentiation (Brand et al., 
2003).  
The Hedgehog proteins are involved in many pathways, but the one relevant for cardiogenic 
fate is Indian hedgehog, which is expresses during gastrulation in the endodermal layer that 
will make contact with the cardiac mesoderm, inducing expression of the Bmp4 gene.  
The Wnt family constituents act through the Frizzled transmembrane receptors. To provide a 
normal heart development, these molecules need to be blocked by specific inhibitors at the 
anterior region of the embryo to induce heart development. 
 
Although FGF and BMP are the most important paracrine factors in heart development, there 
is another family of molecules that plays an important role in this process, named epidermal 
growth factor domain proteins (EGF-domain proteins) (Lee  et al., 1995; Brand, 2003; Nanba et 
al., 2006). This protein family is characterized by extracellular domains that are thought to be 
involved in protein-protein interactions and that show homology to epidermal growth factor 
(EGF) (Beckingham et al., 1998). 
Intercellular signalling mediated by EGF-containing ligands and their cognate receptors are 
important regulators of growth and development. EGF domains are modular protein subunits 
found singly or in tandem, mostly in the extracellular milieu, where they are involved in a 
diverse array of functions (Wouters et al., 2004). Structurally, the EGF domain is typically 
described as a small domain of 30–40 amino acids primarily stabilized by three disulfides 
bridges. Like FGF molecules, EGF uses the receptor tyrosine kinase (RTK) to transmit its signal 
to the cell interior. 
 
10 
 
These receptors all present kinase activity directed against tyrosine residues located both 
within the receptor itself (autophosphorylation) and on target downstream molecules. Ligand 
binding activates the kinase which is required for cellular responses (Fig. 1.2.1) (Wells, 1999). 
EGFR is a 170 kDa transmembrane glycoprotein and it is present on all epithelial and stromal 
cells as well as glial and smooth muscle cells (Wells, 1999). 
 
The integrated biological response to EGFR activation varies from mitogenesis to apoptosis, 
migration to differentiation or dedifferentiation even in the same cell depending on the 
context, which includes cell density, type of matrix, other cytokines, and even the position 
within the tissue (Wells, 1999). 
 
 
  
 
Moreover, outside the cell, several classes of cell surface developmental signalling proteins 
with roles in cell-cell, or cell-extracellular matrix adhesion have proved to be Ca2+-binding 
proteins. One of these molecules is the EGF-domain protein, together with integrins and 
cadherins (Beckingham et al., 1998).  
It is believed that binding of Ca2+ by EGF-like domains functions to establish and stabilize the 
relative orientation of the EGF-like domains and thereby determine the overall shape of the 
molecule (Beckingham et al., 1998). The role of Ca2+ as a key and pivotal second messenger in 
cells depends largely on a wide number of heterogeneous so-called calcium binding proteins 
(CBP), which have the ability to bind this ion in specific domains and act as Ca2+-modulated 
sensors, decoding Ca2+ signals (Yáñez et al., 2012). 
Extracellular matrix plays an important role along different stages of heart development, when 
cellular movement and reshuffle take place. One of this crucial moments is gastrulation, in 
which cardiac mesoderm is specified. An integral component of gastrulation in all organisms is 
epithelial to mesenchymal transition, a fundamental morphogenetic event through which 
epithelial cells transform into mesenchymal cells (Ohta et al., 2010). 
An epithelium is composed of a sheet of epithelial cells that are closely associated with one 
another, like hipoblast and epiblast. By the other hand, mesenchymal cells generally adhere to 
Fig. 1.2.1 – The model for ligand-dependent 
activation of the EGF receptor at the plasma 
membrane, which depicts contribution of the 
extracellular, transmembrane and the 
juxtamembrane domains to receptor 
dimerization (adapted from Jura et al, 2011). 
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their neighboring cells less tightly, being loosely associated and completely surrounded by 
extracellular matrix. Thus, EMT is a coordinated series of events involving loss of cell-cell and 
cell-extracellular matrix interactions and increased cell motility of epithelial cells. 
All these diffusible molecules, particularly, BMP, FGF, EGF and calcium; membrane receptors, 
namely TGF-β, FGFR and EGFR; and signalling cascades,  principally the Ras/MEK/ERK pathway, 
are involved in central steps of heart development, particularly in the earliest, as it will be 
further discussed. 
 
 
1.3. Human Embryonic Stem Cells 
The foundation of mammalian development and embryonic stem cell biology is pluripotency. 
Pluripotency is defined as the capacity of individual cells to self-renewal or divide to originate 
all lineages of the mature organism in response to signals from the embryo or the cell culture 
environment (Wray et al., 2010). Embrionic stem cell lines are derived from pre-implantation 
embryos and retain these characteristics. 
Many studies performed in mouse embryonic stem cells describe them 1. as tumorigenic, 
because they produce teracarcinomas when injected into adult mice; 2. as capable of 
complete integration into a developing embryo after being reintroduced into the blastocyst; 3. 
as being able to colonize the germ line and as such of generating chimaeric animals; 4. as 
competent to undergo multilineage differentiation and produce endoderm, mesoderm, and 
ectoderm; 5. as able to proliferate indefinitely;  and finally, 6. As being able to produce two 
identical stem cell daughters when they divide (symmetrical self-renewal) or one stem cell 
daughter and one differentiated cell (asymmetrical self-renewal) (Burdon et al., 2002). 
These characteristics, which are largely shared by Human Embryonic Stem Cells (hESCs), confer 
them the potential to generate valuable differentiated cell types for drug development, for cell 
replacement therapies, and for gene delivery therapies. Moreover, stem cells can be used for 
gene targeting in order to create mutant cell lines to study gene function or to create mutant 
mouse models for studying diseases. 
As such, embryonic stem cells represent a unique alternative model to investigate the basic 
principles of in vivo mammalian heart development (Kehat et al., 2001). Great similarity in 
genetic and epigenetic programs during embryonic development and embryonic stem cells 
differentiation have been described including the activation of the expression of transcription 
factors, cell receptors, tissue specific proteins and ion channels. 
The gene-expression signature of pluripotent ES cells is relatively well known. Genetic studies 
identified three transcription factors present in the inner cell mass, which expression is 
remained and sometimes enhanced in embryonic stem cells. These are: Oct4 (octamer-binding 
protein 4), Sox2 (SRY (sex-determining region Y) box 2) and Nanog (derivation from the 
mythical Celtic land of perpetual youth). (Gilbert, S., 2003; Boyer et al., 2005; Chambers and 
Tomlinson, 2009). Oct4, Sox2, and Nanog all bind to their own promoters, as well as to each 
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other’s promoters (Boyer et al., 2005) and together they regulate the transcriptional 
regulatory hierarchy that specifies embryonic stem cell identity. Furthermore, Oct4, Sox2, and 
Nanog are thought to maintain the undifferentiated state of ES cells also by contributing to the 
repression of lineage specification factors (Jaenisch and Young, 2008). 
Differentiation of ES cells towards cardiogenesis is characterized by a temporally and spatially 
ordered cascade of gene expression. Along this cascade, Brachyury expression, which specifies 
mesoderm, is followed by Gata4 and Nkx2.5 expression, which lead to the expression of Mhc, 
a cardiomyocite maturation specific gene (Kouskoff et al., 2005). 
During heart development in vitro, multipotent mesoderm cells give rise to cardiac progenitor 
cells. These cells can originate all the lineages of the heart, namely myocites (Gilbert, 2003; 
Jaenisch and Young, 2008) (Fig. 1.3.1). 
 
 
 
In order for hESCs to be of use for tissue replacement therapies it must be possible to direct 
their differentiation along specific pathways to produce a pure population of the desired. No 
contamination with undifferentiated ES cells can be tolerated because of the risk of 
subsequent tumour formation. (Nichols, 2001) 
The human ES cells H9 line, used in this study, was derived by Thomson and colleagues in 1998 
and characteristically retains a normal XX karyotype and expresses high levels of telomerase 
activity (Thomson et al., 1998).  
To obtain mesodermal cells from hESCs a two step protocol was performed. A combination of 
three different factors: FGF2, phosphoinositide 3-kinase (PI3K) inhibitor (LY294002) and BMP4, 
herein referred to as FLyB, was used to obtain early mesoderm. The first two have been 
reported as inductors of mesoderm differentiation (Bernardo et al., 2011) and the PI3K 
inhibitor facilitates differentiation of hESCs (McLean et al., 2007). As referred before, during 
embryogenesis, specification of all kinds of mesoderm, including lateral plate mesoderm, 
follows a posterior-anterior BMP gradient along the primitive streak, so once cells are in that 
first differentiated state, they can be induced to differentiate towards lateral plate mesoderm 
(second step of this protocol) with the addition of FGF2 and high BMP4 (FB50) (Cheung et al., 
2012). 
 
Fig. 1.3.1 – The stem cell concept. Cascade from pluripotent stem cell through mesenchymal stem cell 
and cardiac progenitor cell, to the well differentiated cell (cardiomyocyte) (adapted from Gilbert, 2003). 
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1.4. Developmental Biology as a Biomedical Science 
Developmental biology of the heart as a medical science comprises other emerging disciplines 
such as regenerative medicine, cell therapy and stem cell biology. Scientific research focused in 
studying heart development in all these areas has as ultimate objective the restoration of the 
myocardial function of a sick heart.  
In man, about 1 per 100 live-born infants has some form of congenital heart malformation, 
while the incidence of prenatal fatal congenital malformations is estimated to amount to 5–
10% of abortions (Brand, 2003). Moreover, according to the world’s health organization 
(WHO), the leading cause of adult deaths is ischaemic heart disease, amounting to 12.8 % over 
all deaths. Occlusion of a coronary vessel and the resultant myocardial ischemia rapidly results 
in myocardial necrosis followed by scar formation. When the ischemic myocardium is 
reperfused, there is a rapid onset of contraction band necrosis and an intense inflammatory 
cascade.  It has been well established that adult cardiac myocytes do not replicate, thus these 
pump units are not actually replaced (Jackson et al., 2001). 
Thus, there is hope that understanding how the cardiac muscle is induced during embryonic 
development will have an impact on therapeutic approaches for cardiac regeneration and cell 
substitution (Brand, 2003). 
With this in mind, our laboratory has strive to identify novel genes required for the correct 
development and differentiation of the vertebrate heart cell lineages by using Affimetrix 
GeneChip® Chicken Genome arrays (Bento et al., 2011). In this experiment a candidate heart 
specific gene, that for its own and its product characteristics, was chosen to be further studied. 
This gene is Ccbe1 (calcium-binding EGF-like domain 1) and it is the central gene studied in this 
Master Thesis. It had already been reported that mutations in Ccbe1 result in a severe 
lymphatic system phenotype both in mouse (Bos et al., 2011) and in zebra fish (Hogan et al., 
2009) but its role in the heart remains elusive. Moreover, human CCBE1 gene also being 
associated with Hennekam syndrome, a disorder characterized by abnormal lymphatic system 
development causing generalized lymphedema, intestinal lymphangiectasias, some of the 
patients carrying a mutated hCCBE1 gene were also shown to possess congenital heart defects 
including hypertrophic cardiomyopathy and ventricular septal defects (Connell et al., 2009; 
Alders et al., 2009).  
Besides that CCBE1 has been described as being down regulated in breast and ovarian cancers, 
by hypermethylation of its promoter (Yamamoto and Yamamoto, 2007; Barton et al., 2010). In 
addition, it has been proposed that loss of CCBE1 expression may promote ovarian 
carcinogenesis by enhancing migration and cell survival (Barton et al., 2010), and so being a 
tumour suppressor gene candidate.  
While the importance of mCcbe1 for the development of the lymphatic system appears to be 
indisputable, its role in cardiac development has not been investigated in detail despite the 
increasing evidence of its potential role in cardiogenesis.  
In sum, it is known that Ccbe1 is expressed in cardiac precursors in the mouse, Ccbe1 
homozygous mutation cause lethality in both mouse and zebra fish, and the same kind of 
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mutation in humans is responsible for a high incapacitating disease. Thus, the study of Ccbe1 
function in heart development could unveil important findings and ESCs are an invaluable toll 
to ascertain its function in heart development.  
 
 
1.5. CCBE1 in Heart Development 
The screening performed in our laboratory aimed to characterize chick cardiac precursors. (Fig. 
1.5.1). 
Those cells were isolated from electroporated chick embryos with a construct containing EGFP 
expression under the control of a 2.5 kb fragment upstream the ATG of chick Cerberus, a gene 
expressed into cell population such as the anterior mesendoderm, lateral plate mesoderm, 
heart and anterior blood islands or hemangioblasts (cCer; Tavares et al., 2007). The genetic 
profile provided relevant data of the chick heart/hemangioblast precursor lineage identity and 
led to the detection of 301 uncharacterized genes (119 unknown genes and 182 annotated 
genes) that were upregulated in the heart/hemangioblast precursors (Bento et al., 2011).  
 
 
 
 
 
 
 
 
 
Among the annotated genes potentially involved in heart development, chick Ccbe1 was found 
to be upregulated by 7.8 fold in the cardiac progenitors in comparison to the embryonic 
control cells. cCcbe1 gene is conserved across vertebrates with chick Ccbe1 aminoacid (a.a.) 
Fig. 1.5.1 - Differential screening of the E7.5 chick H/HPC population. The characterized 2.5cCar 
promoter drives expression of EGFP reporter construct in the H/HPC population (green) (adapted 
from Bento et al., 2011). 
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Several new genes were identified using 
the Affimetrix GeneChip System. 
 
cCcbe1 gene, coding for an EGF-like domain protein, was chosen to be 
investigated due its possible role in cell fate commitment and 
embryonic heart development (Lee  et al., 1995; Nanba et al., 2006). 
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sequence being 78%, 67% and 79% identical to the mouse, zebrafish and human Ccbe1 
protein, respectively (BLAST-NCBI). Ccbe1 encodes a secreted protein that contains a signal 
peptide, a collagen domain, a calcium binding EGF-like domain and a RGD sequence. 
Preliminary expression analysis using whole mount in situ hybridization (WISH) further 
indicated that cCcbe1 is preferentially expressed in cardiac mesoderm precursors (Bento et al., 
2011). Moreover, knockdown of cCcbe1 during early chick development was shown to result in 
severe heart tube malformations including cardia bifida (formation of two tube-like structures) 
and embryonic heart hypertrophy (M. Bento, unpublished data). Cardia bifida is also a 
phenotype caused by Gata4 or Mesp1 homozygous mutation (Brand, 2003). 
In the mouse, mCcbe1 was shown to be expressed in the major cardiac lineages, namely FHF, 
SHF and proepicardium (Facucho-Oliveira et al., 2011). 
Given that Ccbe1 mutant phenotype in chick, the confirmed presence of CCBE1 in the mouse 
heart and the fact that patients carrying a mutated hCCBE1 gene exhibit congenital heart 
defects (Connell et al., 2009; Alders et al., 2009), CCBE1 appears to be as a novel cardiac gene 
whose study could unveil new insights of heart development and possibly congenital heart 
disease. As such, the study of CCBE1 in a human context is of upmost relevance and hESCs are 
the perfect starting point for such study. 
In humans, CCBE1 is located at the chromosome 18 and it is 262.130 kb length (Fig. 1.5.2). 
hCCBE1 has 11 exons, and the second intron has 216.390 kb. According to Ensembl CCBE1 has 
two coding transcripts, one coding for a protein with 135 aa and the other coding for a larger 
protein with 406 aa. It is believed that the 406 aa protein is an active form. 
 
 
 
 
As described above, CCBE1 contains an EGF-like domain acting probably as a direct agonist for 
the EGF receptor. It is therefore thought that, similarly to other EGFR agonists, CCBE1 is 
synthesized as a transmembrane precursor and must therefore be proteolytically cleaved by 
matrix metalloproteases (MMP) to release the mature growth factor (Fig. 1.5.3) (Gschwind et 
al., 2001). 
By acting through the EGFR, it is expected that CCBE1 signal is transduced via a number of 
signaling pathways, namely, the Ras/MEK/ERK [MEK (Mitogen activated protein (MAP) kinase 
kinase), ERK (Extracellular-signal-Regulated Kinase)] pathway, the PI3K (phosphatidylinositol-3-
OH kinase)-dependent signals, the JAK/STAT (Janus kinase/ Signal transducer and activator of 
transcription) pathway and the PLCγ/DAG/PKC (Phospholipase c-γ/ Diacylglycerol/ Protein 
kinase-C) (Nyati et al., 2006).  
 
Fig. 1.5.2 – CCBE1 transcript. The vertical bars represent the 11 exons and the spaces between them 
represent the introns (from Ensembl, 2012). 
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The purpose of this Master study was to extend the knowledge on Ccbe1 role in heart 
development to the human context using embryonic stem cells. To achieve this aim, hESCs 
were grown in chemically defined medium and either kept undifferentiated or induced to 
differentiate towards cardiac progenitor cells. The expression, function and regulation of 
CCBE1 were accessed in pluripotent and differentiated cells. To aid the characterization of 
CCBE1 role, CCBE1 knock down lines were generated using shRNAs. Additionally knock down 
lines were generated for ISL1 and BRA genes which according to this study are two candidate 
CCBE1 regulators.  
 
 
 
 
 
 
 
 
 
Fig. 1.5.3 – EGFR signaling. After being cleaved by a 
MMP, the EGFR ligand binds to its receptor, initiating a 
number of signalling cascades. Here are represented 
the four main downstream signalling pathways 
regulated by EGFR. (adapted from Gschwind et al., 
2001 and Burdon et al., 2002; Nyati et al., 2006).  
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2. MATERIALS AND METHODS 
 
2.1. Human Embryonic Stem Cells Culture in Chemically Defined Conditions 
Three main things are necessary to keep H9 human embryonic stem cells (hESC) in culture – 
the right coating, appropriate and timely splitting and maintenance with regular feeds and 
fresh growth factors. 
Before plating the cells, the dishes have to be coated, first with porcine gelatine (Sigma) 0.1% 
in embryo tested water (Sigma) for 15-60 minutes at room temperature (RT), and secondly, 
with mouse embryonic fibroblasts medium (MEF medium (Table 2.1.1)) containing 10% fetal 
bovine serum (Hyclone) over-night (minimum 3h required) at 37oC incubator and 5% CO2. 
Plates last up to 7-8 days but can be recoated with MEF medium after that.  
Splitting is the critical step. It has to be done carefully, otherwise, cell culture quality can be 
lost. It has several intermediate steps. hESCs colonies are washed in phosphate buffered saline 
(PBS) without Ca2+/Mg2+ (Sigma) for 1-2 minutes at RT (1ml/ well of 6 wells plate). This causes 
the detaching of the cells from the growing surface and from each others.  
Next, cells are scraped off the dish in Chemically Defined Medium (CDM) (Table 2.1.1) with a 5 
ml pipette and dissociated into clumps by pipetting up and down 1-4 times. If the cells are 
going to be cultured in pluripotency medium, clumps should have a big size (20-30 cells/ 
clump), if the objective is to perform a differentiation experience clumps should be smaller 
(10-15 cells/ clump).  
After scraping, the cellular suspension is pipetted into a 15ml falcon tube and left for 5-10min 
until clumps gravitate to the bottom of the tube. The top medium (“supernatant”), which 
contains differentiated cells, is discarded by aspiration.  
Cells are resuspended in CDM containing 10 ng/ml Activin A (R&D Systems 338-AC), 12 ng/ml 
FGF2 (R&D Systems 233 FB) and 14µg/ml insulin (pluripotency/ hES medium) and clumps are 
plated at low density (100-300 clumps/well) on the FBS-coated 6 wells plate (previously 
washed with PBS) in CDM enriched with the growth factors described above.  Usually cells are 
plated in a 1:6 to 1:9 dilution factors.  
It is important not to move the plates during the first 12-24h, so that colonies can attach 
properly.  Cells are left in culture during 5-7 days, before the next split, until the colonies reach 
a large size (4 to 6 times bigger than colonies grown on feeder) and the culture becomes 
confluent. During this time, cells are fed every 48h. If many dead cells are observed, the 
culture has to be washed with PBS, before adding fresh medium and more frequent feeds 
need to be done.    
For differentiation into cardiac precursors, Bovine Serum Albumin (BSA) was substituted by 
PVA (Polyvinyl Alcohol) in the CDM. Polyvinyl Alcohol is a BSA substitute, used in 
differentiation medium, because there is no batch variation.  
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To obtain cardiac progenitors, a protocol based in two different defined media is used. 12-24h 
after the splitting, pluripotency medium is changed to FLyB medium, which consists of CDM-
PVA enriched with FGF2 (20 ng/ml, zebrafish, recombinant, gift of Marko Hyvönen), LY294002 
10 μM (Sigma), and BMP4 10ng/ml (R&D Systems) for 36h. FLyB induces early mesoderm 
differentiation. The second stage of differentiation protocol, which induces lateral plate 
mesoderm differentiation, consisted of treating cells with CDM-PVA + FGF2 20 ng/ml + BMP4 
50 ng/ml for the next 3.5 days. All experiments were repeated twice on different passages of 
cells to ensure that the patterns of gene expression described were reproducible.  
 
Human ESC culture conditions for CCBE1 characterization experience 
Cells were grown in 12 wp and collected for RNA extraction or fixed for immunocytochemistry 
at nine different time points: day zero (d0) corresponding to undifferentiated cells, cultured in 
hES medium, and eight time points for differentiated cells (d1, 36h, d2, 60h, d3, d4, d5, d6), 
along the FLyB+FB50 differentiation protocol. For each time point three biological replicates 
were collected.  
 
Culture conditions for CCBE1 knock down experience 
Cells were grown in 12wp and collected for RNA extraction at four different time points: day 
zero (d0) corresponding to undifferentiated cells, and three time points of differentiated cells 
(36h, d3, d5), along the FLyB+FB50 differentiation protocol. For each time point three 
biological replicates were collected.  
 
Medium Components Quantity Concentration Company 
MEF 
Advanced DMEM F12 450ml  Invitrogen, 12634028 
FBS 50ml 10% Biosera, S04253S181S 
L-Glutamine 5ml 2mM Invitrogen, 25030024 
-Mercaptoethanol 350µl 10mM Sigma, M6250-100ML 
     
CDM 
BSA/PVA 
IMDM 250ml  Invitrogen, 21980065 
F-12 250ml  Invitrogen, 31765068 
BSA or PVA 2.5g or 0.5g 
5mg/ml or 
1mg/ml 
Europa bioproducts 
EQBAC62 lot BAC62-
624 
Conc. Lipids 5ml 1% Invitrogen, 11905031 
Insulin 700l 14g/ml Roche 1376497 
Transferrin 250l 15g/ml Roche 652202 
Monothioglycerol 20l 450 M Sigma M6145 
Pen/Strep (optional) 5ml  Invitrogen, 15140122 
     
Gelatine 
Gelatine 0.5g 1mg/ml Sigma, G1890-100G 
Water for Embryo Transfer 500ml  Sigma, W1503-500ML 
 
Table 2.1.1 – Media composition. 
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2.2. RNA extraction, cDNA synthesis and Semi-quantitative PCR  
RNA extraction was performed using a RNeasy Mini Kit (Qiagen). All samples were treated with 
RNase-Free DNase (Qiagen). RNA concentration was measured in a Nanodrop (Thermo 
Scientific).  
To synthesize cDNA from RNA, a Maxima® First Strand cDNA Synthesis Kit (Fermentas) was 
used. This kit consists of three components – Maxima Enzyme Mix, which contains Maxima 
Reverse Transcriptase and Thermo Scientific RiboLock RNase Inhibitor; 5X Reaction Mix, which 
contains reaction buffer, dNTPs, oligo (dT)18 and random hexamer primers; water nuclease-
free. For each sample, a reaction mix with a 10 µl final volume was prepared. The components 
were added as indicated bellow: 
5x Reaction Mix – 2 µl 
Maxima Enzime Mix – 1 µl 
Templete RNA – volume equivalent to 500 ng  
Water – to 10 µl 
 
Reverse transcription was performed following the program described bellow: 
Primers Annealing - 10 minutes at 25oC 
Polymerization - 15 minutes at 50oC 
Enzyme inactivation - 5 minutes at 85oC 
All samples were treated with RNaseH and diluted 30 times. The ssDNA was directly used in 
semi-quantitative real time Polymerase Chain Reaction (qPCR). 
qPCR mixtures were prepared using a Fast SYBR® Green Master Mix (Applied Biosystems, 
4385614). This product contains SYBR Green I Dye (fluorescent intercalating dye which binds to 
the double stranded DNA), AmpliTaq®Fast DNA Polymerase UP (Ultra Pure), Uracil-DNA 
Glycosylase (UDG, prevents the reamplification of carryover PCR products by removing any 
uracil incorporated into single- or double stranded amplicons), ROX™dye Passive Reference 
(allows for correction of well-to-well variation due to pipetting inaccuracies and fluorescence 
fluctuations), nucleotides (dNTPs) and optimized buffer components. qPCR reaction mixes 
were prepared to a 10 µl final volume, as indicated: 
Syber Mix: 5 µl 
Forward Primer: 0.2 µM 
Reverse Primer: 0.2 µM 
Template DNA: 3 µL 
Water: 1.6 µl 
Human primers for qPCR were design using a primer design software (Primer3) and their 
sequences are shown on Table 2.2.1. 
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qPCR Reactions were performed in a 7500 Fast ABI Instrument, according to the following 
program: 
 
AmpliTaq®Fast DNA Polymerase, UP Activation – 20 seconds at 95oC 
Desnaturation – 3 seconds at 95oC 
Annealing/ Extension – 30 seconds at 60oC 
40 cycles 
Each sample was run in duplicate and normalised to Porphobilinogen Deaminase (PBGD) in the 
same run. Error bars on all qPCR graphs represent standard deviation from three independent 
biological replicates.  
The 2−ΔCTmethod (Livak et al., 2001) was used to analyze the relative changes in gene 
expression from real-time PCR experiments, in which 
 2−ΔCT = 1 (PBGD primers efficiency) + 1 (CCBE1 primers efficiency) - (CT gene of interest- CT housekeeping gene)  
 
 
2.3. Generation of Human ESC knockdown lines  
Stable knockdowns (KD) of CCBE1, ISL1 and BRA were carried out with pLKO.1-shRNA vector 
(Thermo Scientific, Sigma) by Lipofectamine 2000 transfection. A Scrambled pLKO.1-shRNA 
vector (Thermo Scientific, Sigma) was used as a control. Stable clones were screened by PCR 
and the percentage of knockdown was determined by comparison to expression in the 
scrambled control transfected lines.  
 
Gene Forward Reverse 
BRA TGCTTCCCTGAGACCCAGTT GATCACTTCTTTCCTTTGCATCAAG 
CCBE1 GAGATGGTTCTAAGGGGAGA ATGTCAGCCAGCATAAGTAGCA 
GATA4 TCCCTCTTCCCTCCTCAAAT TCAGCGTGTAAAGGCATCTG 
ISL1 AGATTATATCAGGTTGTACGGGATCA ACACAGCGGAAACACTCGAT 
KDR TTTTTGCCCTTGTTCTGTCC TCATTGTTCCCAGCATTTCA 
MESP1 AGCTTGGGTGCCTCCTTATT TGCTTCCCTGAAAGACATCA 
MESP2 GCAGTGTACCAGGGTCTCTCT ACTGTGGCTCCAGCACCT 
NANOG CATGAGTGTGGATCCAGCTTG CCTGAATAAGCAGATCCATGG 
NKX2.5 CAAGTGTGCGTCTGCCTTT CAGCTCTTTCTTTTCGGCTCTA 
OCT4 AGTGAGAGGCAACCTGGAGA ACACTCGGACCACATCCTTC 
PBGD ATTACCCCGGGAGACTGAAC GGCTGTTGCTTGGACTTCTC 
SOX2 TGGACAGTTACGCGCACAT CGAGTAGGACATGCTGTAGGT 
Table 3.2.1 – Forward and reverse sequences of primers for qPCR. 
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Vectors came in glycogen stock (E.coli). DNA was amplified and purified using a Plasmid Maxi 
Kit (Qiagen) and following manufacturer’s instructions. 
To expand the culture, cells were picked from the glycogen stock and grew in 2ml LB medium 
supplemented with the appropriate selective antibiotic (ampicilin, 50ng/ml). After growing 
over-night at 37oC, the starter culture was diluted 1/125 into selective LB medium and grown 
again at 37oC for 12 hours. Several steps were followed, namely: bacterial cells resuspention; 
cell lysis; genomic DNA, proteins and cell debris neutralization by a precipitated material 
formation. Then, the plasmid DNA was washed and eluted using a QUIAGEN-tip which contains 
a column with chemical affinity to DNA. After that, a precipitation step was performed by 
adding isopropanol to the eluate, followed by 70% ethanol washing. Finally, each vector was 
redissolved in TE (Tris-HCl, EDTA) buffer.   
 
 
2.4. Transfection using Lipofectamine 2000 
Prior to transfection cells were plated in small colonies and at low density. Transfection was 
performed two days after the plating. 
It was used 1 well of a 6-well plate per vector. In this experiment five different CCBE1 
(TRCN0000055473; TRCN0000055474; TRCN0000055475; TRCN0000055476; 
TRCN0000055477 (Thermo Scientific)) (Table 2.4.1) and five ISL1 (TRCN0000014893; 
TRCN0000014894; TRCN0000014895; TRCN0000014896; TRCN0000014897 (Thermo 
Scientific)) vectors were used to transfect cells. BRA KD line was performed with only one 
vector (TRCN0000005481 (Sigma)), previous tested by Tiago Faial. 
 
Vector 
Target sequence in the 
corresponding DNA (5’-3’) 
Gene location 
TRCN0000055473 CCGAGTGCTGTGTACTTGTTA 4th exon 
TRCN0000055474 CCATGAGAAGTCTGAGAACAT 6th exon 
TRCN0000055475 GCTACTTATGCTGGCTGACAT 11th exon 
TRCN0000055476 GAAGCCATACTGTCTGGATAT 4th and 5th exons 
TRCN0000055477 GTTCCCTTTACCTCAGGAATT 11th exon 
Scrambled  - 
 
 
 
 
 
Table 2.4.1 – CCBE1 shRNA vectors sequences and gene pair location. 
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Transfection protocol per each well: 
Transfection preparation 
Two different solutions were prepared; one with 10 μl lipofectamine in 250 μl OptiMEM, and 
the other had 4 μg plasmid DNA diluted in 250 μl OptiMEM. After 5 min at room temperature 
(RT), both solutions were mixed and incubated for 20 min, to allow for lipid-DNA complexes to 
form. 
Cell transfection 
First of all, cells were prepared for transfection, i.e. wells (12 of a 6wp, in total) were washed 
with PBS and covered with 1ml OptiMEM. 
After that, DNA-lipofectamine complexes were added drop by drop to each well. To 
homogenise the medium, plates were mixed gently by rocking the plate back and forth. 
Cells were incubated at 37°C in a CO2 incubator. 10 hours later, the transfection mixture was 
removed and hES medium was added. 
Selection antibiotic - puromycin (1μg/ml) - was used to supplement hES medium, 48h later and 
thereafter. 
Picking 
From the day puromycin is added cell death starts to take place and about 95% of the cells die 
within the next couple of days. Surviving cells were left to grow during approximately 5 days.  
6 colonies from each well were picked to 6 different wells of a 12wp. At the end, there were 30 
CCBE1 KD clones, 30 ISL1 KD clones, 6 BRA KD clones and 6 Scrambled. 
After 3 days, each clone was split in a 1:2 proportion. There were 2 wells per each clone, one 
for RNA extraction and qPCR analysis and the other one to keep in culture. 
 
 
2.5. Immunocytochesmistry  
Cells were grown in 12wp. When ready, medium was removed from plates and cells were fixed 
for 10 min in ice cold 4% ParaFormolAldeyde (PFA)/PBS. Fixative was removed and cells were 
washed three times in PBS.  
To allow antibody entrance and avoid unspecific binding, cells were permeabilized in PBST 
(PBS +0.01 % Triton X100) for 10 min and blocked for 1 h in blocking buffer (PBST + 5 % donkey 
or goat serum)at room temperature. 
Primary antibody incubations were performed in blocking buffer (200 µl/well), over-night at 
4°C, in a humidified chamber as follows: rabbit anti-CCBE1 (1:75, Sigma), goat anti-NANOG 
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(1:200, R&D Systems), goat anti-BRACHYURY (1:150, R&D Systems), and goat anti-Isl1 (1:100, 
ABCAM). On the next day, cells were washed three times for 5 minutes in PBST.  
Fluorescently labelled secondary antibodies (IgG, 1:400) were added for 1 h at room 
temperature as follows: Alexa 488 donkey anti-goat and Alexa 594 goat anti-rabbit 
(Invitrogen). From this step on, plates were kept in the dark.  
Three washes in PBST for 5 minutes were performed. DAPI was added to the last wash 
(1:10000, Sigma). Cells were washed again twice in PBST. 
Staining was observed in a fluorescence microscope. 
 
 
2.6. Chromatin Immunoprecipitation 
This protocol has four main steps, crosslinking and sonication, immunoprecipitation, bead 
washing and samples purification. Before start the immunoprecipitation, it is necessary to 
have enough number of cells, so hESCs were grown in three 10 cm plates until the culture 
become clearly confluent (2 x107 to 5 x 107 cells). Then, they were collected as described 
below:  
1) Cells were crosslinked with 10mM Dimethyl 3,3′-dithiopropionimidate dihydrochloride 
(DTBP, Sigma, D2388) and 2.5mM 3,3′-Dithiodipropionic acid di(N-hydroxysuccinimide 
ester) (DSP, Sigma, D3669) in PBS at RT for 15mins. 
 
2) Further crosslinking was done on plates: 125 µL of 40% formaldehyde (final conc. 1%) 
added to 5 mL PBS, incubate rocking for 15min at RT. 
 
3) 312.5 µL of 2 M Glycine (final conc. 0.125M) were added and cells incubate for a 
further 5-10min to neutralise formaldehyde. 
 
4) Plates were washed twice with 5mL ice cold PBS and detached cells by scraping in 3 mL 
cold PBS plus protease inhibitors mix (1x) and PMSF (0.4 mM) and pooled in a 50mL 
falcon tube. 
 
5) Cells were next span for 6 min at 1,200 rpm and frozen at -80oC until ready to continue 
the protocol. 
 
 
When ready, the samples were thawed and prepared for sonication, as follows:  
1) Resuspend pellet in 2mL Cell Lysis Buffer (Add protease inhibitors, 10µL/mL PMSF) and 
incubate on ice for 10 min. 
 
2) Spin at 1,800 rpm at 4C for 5min. 
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3) Resuspend pellet (nuclei) in 1.25mL Nuclei Lysis Buffer (add PI, PMSF) and incubate on 
ice for 10min. 
 
4) Add 0.75mL of IP dilution Buffer (add PI, PMSF) and keep samples on ice. 
 
Sonication (Misonix 4000) was performed using a microtip probe, 60% power, 15secs 
on/45secs off. This procedure originated DNA fragments about 1000-2000bp length. 
Proteins, lipids and cellular debris were despised by spinning the samples at 14,000 rpm for 
5min at 4oC. Supernatant, which contains crosslinked DNA, was kept and transferred to a new 
tube and 3.5 mL IP dilution buffer, supplemented with PI and PMSF. Solutions were mixed 
gently. 300 µL of sample was removed and frozen (Input). 
To continue to immunoprecipitation, samples were dispensed into an appropriate number of 
tubes, accordingly to the different IP performed. Each sample was incubated shaking/rotating 
at 4oC overnight, with 5 µg of antibody (the same used in ICC). 
Magnetic beads were used to catch Ab, which binds to transcription factors, which in turn are 
bound to DNA fragments. 
First, beads (100 µl per IP) were washed three times with 1 ml Block Solution. Beads were 
resuspended in 100 μl Block Solution, per IP. 
100µl magnetic beads were added to each IP, which were incubated shaking/rotating for 
1h.30min at 4oC. 
Next, beads were washed with three different buffers, and afterwards, protein complexes 
need to be eluted from the beads. This wash process was performed with samples always kept 
on ice and it was performed as described: 
1) Collect the beads using a magnetic rack; the complex protein-DNA of interest should 
now be bound to the beads. 
 
2) Add 500µL of IP Wash 1, collect the beads as above. Repeat washing with IPW1. 
 
3) Add 500µL of IP Wash 2, collect the beads as above. 
 
4) Wash beads twice with 500 µL TE. 
 
5) Add 150µL Elution Buffer, put in a themomixer 30min at 65°C with vortexing (1,200 
rpm).  
 
6) Collect the beads as above and transfer supernatant to a new tube and repeat the 
elution. Final volume should be 300µL per IP. 
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The next and last step consisted in samples purification, removing of crosslinks, degrading RNA 
and proteins, and DNA precipitation. Samples were treated as follows: 
1) Treat all samples (including Input) with 100mM DTT for 30mins at 37°C, add 15µL 5M 
NaCl and leave ON at 65°C to reverse chemical crosslinking. 
 
2) Add 8µL RNase A (1 mg/mL stock), incubate at 45°C 2 h. 
 
3) Add 4µL Proteinase K (20 mg/mL stock) and incubate at 55°C 2 h. 
 
4) Add 300µL phenol/chloroform, vortex vigorously and spin at 14,000 rpm for 5min (RT). 
 
5) Add 30µL 3M NaAc pH5.2 and 30µg glycoblue, vortex, add 750µL 100% EtOH and 
incubate at –80C for at least 30min to precipitate the DNA. 
 
6) Spin at 14,000 rpm for 30 min at 4°C. 
 
7) Wash pellet with cold 70% EtOH and spin at 14,000 rpm for 5min at 4°C. 
 
8) Remove EtOH and dry pellet. 
 
9) Add 30µL sterile dH2O to IP samples and 100 µL to Input samples. 
 
Buffers used in this protocol are presented in Table 2.6.1.   
Finally, samples were analysed by qPCR and the amplification results were compared to those 
of the input. Input samples were diluted twice prior to being analysed. ChIP samples were run 
in duplicate and normalised to Input in the same run. Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was used as housekeeping gene. 
Human CCBE1 primers for ChIP-qPCR were designed using the primer design software Primer3.  
 
 
 
 
 
 
Genomic Region Forward Reverse 
5’region TAGTTGGAGGTGGTTTTGTGC GTTGACAGCCCATGCTAGCGC 
Mid region AAGGGCTAAGGTCATTTTCTCC AAAAGAGGCAAAATGGAACAGA 
3’region CATCTGGCGTTCTCTCTATGG TCCCTACCTCTTCTTCCCAAA 
Mid region GTGGCAGGAGTGTAAGATCACC CAAGGAAGAGCTGAGTGGAAAG 
3’region CCTCCAATTAGCACCTCATCA TTCGCAAAAAGAATGCTCAGT 
Table 2.6.1 – Primers sequences for ChIP-qPCR. Primers used in BRA/ISL1 ChIP after 60h of 
differentiation are shown is red and the oligonucleotides used in BRA/NANOG ChIP for pluripotent 
cells are shown with a blue mark. 
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qPCR reaction mixes were prepared to 10µl final volume, as indicated: 
Syber Mix: 5 µl 
Forward Primer: 0.2 µM 
Reverse Primer: 0.2 µM 
Template DNA: 3 µL 
Water: 1.6 µl 
 
 
Reactions were performed in a 7500 Fast ABI Instrument, according to the following program: 
AmpliTaq®Fast DNA Polymerase, UP Activation – 20 seconds at 95oC 
Desnaturation – 3 seconds at 95oC 
Annealing/ Extension – 30 seconds at 60oC 
45 cycles 
 
Buffers composition is shown in Table 2.6.2. 
 
Buffers Composition 
Cell lysis buffer 10mM Tris pH 8.0, 10mM NaCl, 0.2% NP-40 
Nuclei Lysis Buffer 50mM Tris pH 8.1, 10mM EDTA, 1% SDS 
IP Dilution Buffer 
20mM Tris pH8.1, 2mM EDTA, 150mM NaCl, 
0.01% SDS, 1% Triton X-100 
IP Wash Buffer I 
20mM Tris pH8.1, 2mM EDTA, 50mM NaCl, 
0.1% SDS, 1% Triton X-100 
IP Wash Buffer II 
10mM Tris pH 8.1, 1mM EDTA, 0.25M LiCl, 1% 
NP-40, 1% Deoxycholic acid, sodium salt 
Elution Buffer 100mM NaHCO3, 1% SDS 
Blocking Solution 0.5% BSA (w/v) in PBS 
 
 
 
 
 
 
 
 
 
 
Table 2.6.2 – Buffers used in ChIP protocol. 
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3. RESULTS 
3.1. CCBE1 Characterization 
In order to establish the expression pattern of CCBE1 in H9 hESCs, cells were cultured in a 
chemically defined medium (CDM) and collected for qPCR analysis and immunostaining at nine 
specific time points during cardiac differentiation. For this, pluripotent cells were exposed to 
growth factors that induce cardiac specification, following a previously described 
differentiation method (Fig. 3.1.1) (Bernardo et al., 2011; Cheung et al., 2012). The expression 
of mesoderm and cardiac specific genes was also analysed to confirm the cells had 
differentiated as expected and ascertain which genes follow the expression pattern of CCBE1. 
RNA was extracted from each sample (27 in total), and later reverse transcribed into cDNA to 
determine the expression levels of various genes by qPCR analysis (Fig. 3.1.2 and Fig. 3.1.3); 
primers sequences can be found in Table 2.2.1 (Materials and Methods). 
Subsequently, real time PCR was performed and the expression levels of each gene were 
normalised to that of Porphobilinogen Deaminase (PBGD) for each sample.  Error bars on all 
qPCR graphs represent standard deviation from three independent biological replicates.  
This experiment was repeated twice on different passages of cells to ensure that CCBE1 
expression pattern was reproducible.  
 
 
 
 
 
 
 
 
Fig. 3.1.1 – Differentiation method. Cells were cultured in CDM-BSA supplemented with Activin A 
and FGF2. To obtain early mesoderm, cells were cultured in CDM-PVA supplemented with FLyB for 
36h, and then with FB50 to obtain cardiac precursors. 
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Interestingly, CCBE1 is highly expressed in pluripotent cells its expression is downregulated in 
early mesodermal cells, and progressively starts to be as differentiation into cardiac precursors 
occurs. Its expression peaks at day D5 of differentiation and between D5 and D6, CCBE1 mRNA 
is clearly downregulated. 
NANOG, a known pluripotent marker, was highly expressed in pluripotent cells and its 
expression decreases upon mesoderm differentiation. On the other hand, the early mesoderm 
genes BRA emerged transiently and peaked at 36h after FLyB treatment. MESP1, the earliest 
marker of cardiovascular progenitors (Bondue et al., 2012), and MESP2, from the same family 
of transcription factors, started to be expressed by D1 and both had a basal expression from 
day 3 and thenceforth. Lastly, the expression of the lateral plate markers ISL1, NKX2.5, KDR 
and GATA4 was increased from D2 of FLyB+FB50 differentiation, peaking between days 4 to 6. 
To complement these transcriptional data, cells were fixed and immunostained at three 
different time points (D0, 36h and D5), with antibodies raised against CCBE1, NANOG, BRA and 
ISL1. 
 
 
 
 
Fig. 3.1.2 - Gene, transcript and cDNA levels. At the gene level the 11 exons and the 10 introns 
are shown. The forward strand is transcribed in mRNA, which was collected and from which cDNA 
was synthesized. Primers were designed to avoid genomic or immature mRNA amplification and 
to assure the amplification of all splice variants. Forward primer was designed to anneal with a 
splice region located within the 9
th
 and 10
th
 exons. Reverse primer was designed 54 pb 
downstream the forward one, in the 11
th
 exon.  
CCBE1 mRNA 
CCBE1 cDNA 
Forward strand 
Reverse strand 
CCBE1 gene diagram 
R primer 
F primer 
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Fig. 3.1.3 – qPCR graphics. Cells were cultured as indicated and collected at D0 
(pluripotency), and at several time points after differentiation has started – D1, 36h, D2, 
60h, D3, D4, D5, D6.  
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The results show the protein data are in keeping with mRNA data. CCBE1 protein is highly 
expressed in pluripotent and cardiac precursor cells, and it is downregulated in early 
mesodermal cells. NANOG has a strong nuclear protein expression in pluripotent cells, with 
most cells expressing this gene. Some of these also express CCBE1, which expression is 
observed in the cytoplasm, as expected for this growth factor since CCBE1 is a secreted 
protein. For the same reason CCBE1, once as a growth factor, CCBE1 can have diffusible 
proprieties; it is not strongly expressed in the extracellular matrix. By 36h of FLyB treatment, 
immunostaining confirms CCBE1 is downregulated upon BRA upregulation. CCBE1 expression 
is then observed at day 5 of FLyB+FB50 treatment, where it colocalizes with ISL1. Curiously, 
CCBE1 is only expressed in ISL1 positive cells, but only a subset of ISL1+ cells co-express CCBE1. 
These results suggest that CCBE1 expression is induced by a pluripotency gene in 
undifferentiated cells and by a cardiac gene in cardiac progenitor cells. It is also possible that 
BRA or another early mesoderm gene blocks CCBE1 expression. 
 
 
3.2. CCBE1 Regulation 
Understanding the regulatory mechanisms controlling CCBE1 expression at a DNA level would 
be highly interesting. . To test the idea that BRA has an important role in this process, possibly 
a repressive role, since when BRA is expressed CCBE1 is downregulated, a ChIP-seq database 
for BRA binding sites in 36h FLyB treated cells (Faial et al., in preparation) was screened. 
Interestingly, several binding sites for BRA were observed in the CCBE1 promoter region. The 
 
Fig. 3.1.4 - Immunostaining performed in pluripotent (D0) and differentiated cells (36h, D5). Samples 
were co-stained for NANOG (green) and CCBE1 (red) at D0; BRA (green) and CCBE1 at 36h of FLyB 
differentiation; and ISL1 (green) and CCBE1 at D5 of FLyB+FB50 differentiation. All samples were 
stained for DAPI, a nuclear marker. 
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three main different binding sites observed were: one located downstream of the transcribed 
region (3’ region), the second one located in the middle (mid) of the gene (middle region), and 
the third one located more upstream in the very beginning of the gene, just after the ATG (5’ 
region). Curiously, the last two regions (mid and 5’) are located within the second intron of 
CCBE1 (Fig. 3.2.1).   
 
 
 
 
 
 
 
 
 
 
These findings confirm that BRA binds and likely regulates CCBE1 expression,  given that, 
CCBE1 expression is the lowest when BRA expression is the highest. 
The obvious thought was that BRA has an inhibitory role over CCBE1. Nevertheless, there is no 
report about BRA having an inhibitory function. Thus, another hypothesis was formulated: 
BRA, rather than inhibiting, activates CCBE1, but only in the presence of a co-activator. BRA is 
expressed, albeit at lower levels, in both pluripotent and cardiac precursor cells (CT(D0)= 31.59; 
CT(60h)= 26.05), which would be in keeping with a requirement of BRA for CCBE1 induction. If 
the hypothesis raised is true, then BRA would need a partner in both contexts in order to 
induce CCBE1 expression. Such partners could be a pluripotency marker gene in the 
pluripotent context, such as NANOG, and a cardiac precursor gene, in cardiac progenitor cells, 
like ISL1. 
Interestingly, there are reported binding sites for NANOG along the CCBE1 gene (Fig. 3.2.2). As 
such, to test the hypothesis that BRA and NANOG interact to induce CCBE1 expression, 
Chromatin Immunoprecitation (ChIP) was performed in pluripotency conditions using 
antibodies against NANOG and BRA. 
 
In this report, three main different binding sites are observed, one located downstream the 3’ 
region, the second one located in the middle (mid) of the gene (middle region), and the third 
one in the CCBE1 beginning (5’ region).  
Fig. 3.2.1 – BRA ChIP-seq after 36h of FLyB treatment. It is showed that there is BRA binding to 
three different regions of CCBE1 gene; two within the second intron, and the third in the 3’ 
downstream region.  
3’                                                                                                                                                                            5’ 
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Amongst some of the NANOG binding regions (consensus sequence CATT) there were several 
BRA consensus sequences (CACACC) and as such primers were designed around these regions 
(Fig. 3.2.3). Three primer pairs were tested, one for each region (5’, mid and 3’), but only the 
primers designed for the middle and 3’ regions had an optimal efficiency value, thus the 5’ 
region primers were not used. After conducting the ChIP protocol in undifferentiated hESCs, 
PCR analysis using the specific primers for each region was preformed. The relative binding of 
the transcription factors cited was determined by comparison with the IgG negative control. 
The results clearly show that there is enrichment of both NANOG and BRA binding to the 
CCBE1 3’ regulatory region, when compared to the control (Fig. 3.2.4). With regard to the 
middle regulatory region, the results suggest that there is no specific binding of either NANOG 
or BRA  due to the high unspecific binding of the IgG control to this region (Fig. 3.2.4). 
A candidate partner for BRA in cardiac progenitor cells is ISL1 because: 1. CCBE1 co-localises 
with ISL1 and 2. BRA and ISL1 have come up as interacting partners in a yeast two-hybrid 
screen (Bernardo et al. unpublished). It has previously been shown in the lab by 
immunocytochemistry analysis that BRA and ISL1 co-localise 60h after cardiac differentiation is 
initiated. Thus, to determine if BRA and ISL1 bind to CCBE1 promoter, cells were grown in the 
FLyB+FB50 condition for 60h and then cells were collected for ChIP. 
ISL1 and BRA consensus regions, CTAATG and CACACC, respectively, were identified along the 
CCBE1 promoter region and three pairs of primers were designed so that the amplicon was 
within them (Fig. 3.2.3). 
 
 
 
Fig. 3.2.2 – NANOG ChIP-seq. NANOG binds in and around the CCBE1 gene, in the same 
regions as BRA. It is seen many other transcription factors can bind to CCBE1 at this specific 
time point. Data from UCSC Genome Browser. 
3’ 5’ 
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The ChIP preformed on cells collected after 60h of FLyB+FB50 treatment showed binding of 
ISL1 and BRA to the CCBE1 mid regulatory region, but not to the than 3’ or 5’ regulatory 
regions (Fig. 3.2.5).  
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Fig. 3.2.4 – BRA/ NANOG ChIP pluripotency. The first graphic represents the NANOG and BRA 
binding to the CCBE1 middle regulatory region and the second one represents NANOG and BRA 
binding to the CCBE1 3’ regulatory region.  Relative NANOG and BRA binding was determined by 
PCR and compared with the IgG control. 
 
 
Fig. 3.2.3 – Zoom in of the three main regulatory regions of the CCBE1 gene. The small lines 
above the image represent the genomic regions where primers were designed, both for BRA/ 
NANOG ChIP and BRA/ ISL1 ChIP. The green one represents the two pairs of primers (one for 
which ChIP) designed for the 5’ regulatory region. The remaining pairs of primers designed for 
the middle and 3’ regulatory regions are represented in blue and orange, respectively. The 
sequences can be consulted in Materials and Methods. 
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These data support the hypothesis that BRA binds to CCBE1 in different contexts where it 
interacts with different partners to activate CCBE1. It further suggests that NANOG and ISL1 
act as co-activators of CCBE1 in pluripotency and cardiac progenitor cells, respectively. 
Another interesting finding is that the regulation of CCBE1 expression is done in different 
regulatory regions according to the differentiation state of the cell and the proteins involved.   
To further determine the roles of BRA and ISL1 in the regulation of CCBE1 expression, knock 
down (KD) cell lines for these genes were generated using Short hairpin RNAs (Fig. 3.2.6). 
 
 
 
 
 
 
 
 
 
Several KD lines were generated for each gene and the clone lines were culture alongside a 
control line (scrambled) in differentiation medium for a maximum of five days and their mRNA 
was extracted for semi-quantitative PCR analysis to evaluate the CCBE1 expression (Fig. 3.2.7 
and Fig. 3.2.8). The expression of CCBE1 was affected in BRA KD cells at d0 and d3, but not at 
36h, when the BRA knock down is strongly evident (Fig. 3.2.7). If BRA worked to repress CCBE1, 
as was hypothesised, CCBE1 expression should have been upregulated at 36h. Subsequently, 
this result does not support a repressing role of BRA over CCBE1 expression. Moreover, CCBE1 
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Fig. 3.2.5 – BRA/ ISL1 ChIP 60h of differentiation. All the graphics represent ISL1 and BRA 
binding to the CCBE1 regulatory regions, 5’, middle and 3’, respectively. Relative NANOG and 
BRA binding was determined by PCR and compared with the IgG control. 
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Fig. 3.2.6 – BRA and ISL1 KD lines. To establish these cell lines a pLKO.1-shRNA vector was 
integrated into the genome by Lipofectamine transfection. The best BRA KD and ISL1 KD 
clones were chosen, with KD percentages of 88.28456 at 36h and 89.69173 at d5, 
respectively. 
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is clearly downregulated by d3 of FLyB+FB50 differentiation in the KD clones, which could be 
explained if BRA was an activator of CCBE1. Thus, the results are in keeping with the thesis that 
BRA activates CCBE1. 
Interestingly, BRA KD cells exhibited upregulated levels of CCBE1 expression in pluripotency 
conditions. As for the ISL1 KD cells, these also exhibited upregulated levels of CCBE1 
expression in pluripotency conditions. Furthermore, after three and five days of culture, there 
was no clear difference between the CCBE1 levels expressed in the scrambled and ISL1 KD cells 
(Fig. 4.2.8) suggesting that the low levels of ISL1 mRNA do not affect much CCBE1 expression. 
Despite that, the ISL1 knock down was not as evident at day three as it was at day five of 
differentiation (there is no significantly difference between ISL1 expression in the KD line and 
in the scrambled line at day 3). It is precisely around this time point (60h), it was hypothesized, 
that together with BRA, ISL1 might have an induction effect over CCBE1. So, if this supposition 
is true, this result would justify the similarity between CCBE1 expression levels in scrambled 
and ISL1 KD cells.  
 
 
 
 
  
0 
1 
2 
3 
4 
5 
d0 36h d3 
CCBE1 
S 
BRA KD 
0 
0.01 
0.02 
0.03 
0.04 
0.05 
0.06 
0.07 
d0 36h d3 d5 
CCBE1 
S 
ISL1 KD 
Fig.  3.2.7 – CCBE1 expression upon BRA KD cells. T-test was performed where *p ≤ 0.05. 
Fig. 3.2.8 – CCBE1 expression upon ISL1 KD cells. 
* 
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3.3. CCBE1 Function 
To better understand the role of CCBE1 in both pluripotent and cardiac progenitor cells several 
CCBE1 KD cell lines were generated. Five different shRNA sequences were used to generate 
five different lines. Of these, two of them (TRCN0000055474 (KD1) and TRCN0000055477 
(KD2)) were most effective at knocking down CCBE1 expression (Fig. 3.3.1). 
 
 
 
Cells that resulted from these transfections were expanded and later studied by real time PCR. 
Interestingly, the results show that the lack of CCBE1 expression affects the expression of key 
pluripotency genes (Fig. 3.3.2) and that of some important cardiac progenitor genes (Fig. 
3.3.3). Maintaining the CCBE1 KD clones was particularly challenging, which was the first 
evidence that CCBE1 is required for keeping cells pluripotent. After repeating the experiment a 
couple of times, it was further confirmed that CCBE1 is required to dowregulate Nanog and 
OCT4 levels and to induce SOX2 expression (Fig. 3.3.2) suggesting that the pluripotency 
circuitry needs CCBE1 to be kept balanced. It was unsurprising therefore to observe that, after 
just a few passages (up to 4), the CCBE1 KD cells lose their KD properties, i.e. the Sh-RNA 
becomes silenced, or they have an adaptive disadvantage when compared with the wild type 
ones (Fig. 3.3.4).  
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Fig. 3.3.1  – CCBE1 expression upon CCBE1 KD cells – first collection. Here are presented the two 
best KD lines collected at D0, one with 34.59391% of CCBE1 expression (KD1) and the second one 
with 20.42849%. 
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Fig. 3.3.2 – NANOG, OCT4 and SOX2 expression upon CCBE1 KD cells – first collection. These 
data report to the CCBE1 KD clones presented in the Fig. 4.3.1. 
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Next, the CCBE1 KD clones were grown in cardiac differentiation medium and the expression 
of cardiac progenitor genes determined by real time qPCR (Fig. 3.3.2).  
The majority of the genes tested was downregulated in both or just in one of the CCBE1 KD 
clones (clone KD2). The reduced levels of CCBE1 expression lead cells to dowregulate the 
expression of BRA, NKX2.5, GATA4 and KDR. However, MESP1 and ISL1 levels of expression did 
not appear to be affected by the CCBE1 knockdown and the results for MESP2 were 
antagonistic; MESP2 expression was upregulated in the KD1 cell line and downregulated in the 
other KD line.  
These preliminary results lead to the conclusion that CCBE1 is quite important to potentiate 
cardiac differentiation, because when it is not present in physiological levels, expression of 
early mesoderm and cardiac precursor genes is downregulated.  Moreover they suggest that 
there is a feedback loop between CCBE1 and BRA given that they appear to regulate each 
other (Figs. 3.2.7 and 4.3.3). 
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Fig. 3.3.4  – CCBE1 expression upon CCBE1 KD cells – fourth passage. The lost of CCBE1 knock down 
in both clones was demonstrated by a qPCR analysis.  
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Fig. 3.3.2 – qPCR graphics - CCBE1 KD cells. Here are presented the two best KD clones 
grown during 36h, three and five days of differentiation. 
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4. DISCUSSION 
 
Much of what is known about the molecular pathways that lead to human cardiovascular 
disorders has come from studying animal models, particularly genetically modified mouse 
models. Although these approaches have been useful and it is possible in many cases to 
translate genetic discoveries from humans to mice, important differences exist between 
rodent and human cells. Recent advances in stem cell and cardiovascular progenitor biology 
now raise the possibility of generating human models of human cardiovascular development, 
physiology, and disease (Musunuru et al., 2010). 
In this report, a reproducible protocol in which human ES cells are used as model of early 
development is described. This method was used in this study to determine the role of the 
secreted protein CCBE1 in cardiac progenitor cells.  
The hESC line H9 was used for this purpose and a two fazed protocol followed in which cells 
were first pushed towards mesoderm and later towards cardiac progenitor cells. When 
exposed to the mesoderm medium (FLyB medium) the H9 cells suffer a cellular reorganization, 
which resembles the process of epithelial to mesenchymal transition (EMT) observed in early 
gastrulation. More specifically, the H9 hESCs pluripotent colonies, which are a compact 
monolayer and circular in shape, lose their compact organization and acquire a mesenchymal 
phenotype when they start to differentiate into the mesodermal lineage. Clearly, there is 
extracellular matrix (ECM) restructuration, which implies degradation of ECM components. 
One of such components could be the protein CCBE1, which is shown in this report to be 
present in pluripotent cells and to suffer drastic alterations of gene expression upon 
mesoderm induction.   
The results presented here suggest that when cells start to differentiate towards mesoderm 
CCBE1 promoter is not being activated, or is being repressed and its product is degraded, since 
CCBE1 expression is downregulated. 
One possible explanation for this phenomenon is based on BMP signalling, one of the 
components of the FLyB medium. It has been reported that BMP signalling could induce EMT 
and disrupt the basal membrane through induction of matrix metalloproteinases (MMP) 
expression, resulting in ECM degradation and, ultimately, in ingressive cell movement during 
gastrulation (Ohta et al., 2010). As such, one could raise the hypothesis that BMP could lead to 
ECM degradation and as such to CCBE1 degradation. 
Furthermore, it has been reported that loss of CCBE1 expression enhances migration of 
ovarian cancer cells in vitro and its overexpression in breast cancer cells inhibits cell migration 
(Barton et al., 2010). Moreover, proliferation assays performed in our laboratory show that 
Ccbe1 knockout fibroblasts exhibit enhanced proliferation rates (Ana Perestelo, unpublished 
data). All in all, this suggests that CCBE1 is usually not expressed or downregulated during cell 
migration, and therefore it is unsurprising to see that upon early mesoderm differentiation in 
culture CCBE1 expression levels are low.  
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As opposed to what is observed upon mesoderm differentiation, CCBE1 is highly expressed in 
both pluripotent and cardiac precursors cells. Since its protein structure contains collagen and 
RGD domains, EGF-like and Ca2+ binding domains, it can be assumed that CCBE1 has an 
important role in cell adhesion and migration. However, the role of CCBE1 in either cell type is 
not known. As such, CCBE1 knockdown lines were generated to address its specific function (if 
any) in pluripotency maintenance and cardiac differentiation.  
CCBE1 KD cells show downregulation of the cardiac marker genes NKX2.5, GATA4, but not of 
ISL1. BRA, an early mesoderm inducer, is also affected negatively by the CCBE1 KD. It can 
therefore be concluded that, when CCBE1 expression is bellow its normal levels, hESCs cannot 
differentiate properly into cardiac mesoderm. These preliminary results raise the hypothesis 
that CCBE1 has an important function in cardiac mesoderm specification and therefore in heart 
development, which is in keeping with what has been described in mouse embryos (Facucho-
Oliveira et al., 2011) and in mES cells (Tiago Justo and Facucho-Oliveira, unpublished data).  
These results could be explained in two different ways. One is that the loss of CCBE1 during the 
in vitro EMT could preclude correct differentiation to occur or, on the other hand, since the 
CCBE1 KD impairs the cells in their pluripotent state, it could be that the CCBE1 KD 
compromises the cells’ capacity to differentiate, due their ‘ground’ state being unstable.  
CCBE1 signal is possibly transduced through Ras/MEK/ERK pathway once it has an EGF-like 
binding domain. This signalling pathway has a pro-differentiation effect and is antagonistic to 
mES cell self-renewal (Burdon et al., 2002). Since CCBE1 is highly expressed in pluripotent cells, 
if indeed CCBE1 signal is transduced via the Ras/MEK/ERK pathway, one could speculate that 
the overall balance of CCBE1 and other pluripotency maintenance genes might determine the 
efficiency of embryonic stem cell self-renewal. To further understand the effect of CCBE1 in 
pluripotency and its role in the switch from the pluripotent state to a differentiated state, 
expression of pluripotent marker genes was analyzed in CCBE1 KD lines. Importantly, the 
successful CCBE1 KD lines lost their KD state in a few passages after being generated, which 
shows that the shRNA vector was rapidly silenced or excised, or in turn, CCBE1 KD cells could 
have died prematurely and been replaced by a minority of non-targeted puromycin resistant 
cells that lingered in the culture, suggesting that CCBE1 plays an important role in 
pluripotency.  
NANOG, OCT4 and SOX2 expressions were affected by the CCBE1 knockdown; i.e. the first two 
transcription factors were upregulated and SOX2 was downregulated. 
A recent report suggests distinct lineage specification roles for NANOG, OCT4, and SOX2 (Wang 
et al., 2012). Loss- and gain-of-function studies coupled with transcriptome profiling have 
shown that while SOX2 represses mesendoderm differentiation, high levels of OCT4 suppress 
ectoderm and promote mesendoderm specification in the presence of BMP4. Furthermore, it 
has been reported that NANOG inhibits ectoderm differentiation (Wang et al., 2012) and 
promotes mesoderm differentiation (Yu et al., 2011). Overall, both KD and OE data strongly 
suggest that, in hESCs, NANOG, OCT4, and SOX2 function as differentiation repressors.  
Based on the results obtained it can be suggested the loss of CCBE1 expression in pluripotent 
cells difficult ectodermal cellular differentiation and potentiates mesendodermal 
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differentiation by rising the expression of NANOG and OCT4 and dowregulating the expression 
of SOX2.  
To further understand the role of CCBE1 in the pluripotent context, complementary 
experiments need to be performed. The preliminary results presented here suggest that CCBE1 
depletion impairs their ability to proper differentiate into cardiac mesoderm, but nothing is 
known about what CCBE1 depletion would cause upon ectoderm and endoderm 
differentiation. It has been reported that transcription factors required for establishment and 
maintenance of the pluripotent also promote signalling that drives progression from this state 
(Wray et al., 2010). Interestingly though when Fgf4, whose expression is regulated by Sox2 and 
Oct4, is depleted in pluripotent mES cells they lose their ability to differentiate into mesoderm 
and neuroectoderm. Curiously, this factor is also important in cardiac development (Brand, 
2003) and uses the same kind of receptor as CCBE1 probably does (tyrosine kinase receptor).  
In sum, the results obtained from the analysis of the CCBE1 KD clones reveal that CCBE1 
protein plays an essential role in mesoderm specification, regulating positively both early and 
later mesoderm markers. This is in keeping with data from mouse and mESCs (Facucho-
Oliveira, data not shown). The data which suggest that CCBE1 has also an important function in 
keeping pluripotent cells balanced is novel and further experiments need to be performed in 
order to confirm the preliminary results present here.  
Another important question raised in this study relates to CCBE1 expression pattern and its 
regulation. CCBE1 is expressed in two completely different cellular contexts: in pluripotency 
and in cardiac mesoderm, while being absent from early mesoderm cells. The expression 
pattern of CCBE1 was determined by mRNA analysis and validated by accessing its protein 
expression by immunocytochemistry. Therefore, different transcription factors are activating 
CCBE1 in these two different states or a repression signal is being produced in early 
mesoderm, the intermediate state between the pluripotent state and the cardiac mesoderm 
state. This hypothesis was tested using two different approaches: chromatin 
immunoprecipitation (ChIP) and knocking down the candidate genes thought to be CCBE1 
regulators. 
Three transcription factors were chosen as candidate CCBE1 regulators: NANOG for the 
pluripotent cellular context; BRA for the early mesoderm context; and ISL1 for the cardiac 
mesoderm differentiation context. NANOG was chosen because ChIP-seq data published on 
the UCSC Genome Browser shows binding of this transcription factor to CCBE1 gene. Similarly, 
BRA was chosen because when it is expressed CCBE1 is downregulated and also because ChIP-
seq data of early mesoderm cells show that BRA binds to CCBE1 (Faial et al., manuscript in 
preparation). Lastly, ISL1 was chosen because it is a crucial gene in cardiac development which 
expression co-localises with that of CCBE1. This study revealed that BRA and NANOG bind to 
the 3’ regulatory region of CCBE1 in pluripotency; while BRA and ISL1 bind to the CCBE1 middle 
region in cardiac progenitor cells. Based on these data it is possible to propose that CCBE1 is 
differentially regulated according to the cell state. These two regulatory mechanisms are likely 
to depend on BRA interacting with NANOG or ISL1 to bind to two different regions of the 
CCBE1 gene. Further analysis needs however to be performed to validate these preliminary 
data.  
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This study went a little step further in order to determine if indeed BRA, ISL1 and NANOG 
regulate CCBE1 by generating and analysing BRA and ISL1 KD lines. As for the BRA KD, results 
show that CCBE1 expression is unchanged at 36h of FLyB differentiation. This result suggests 
that BRA does not have a repressive effect over CCBE1. Interestingly though, at D3 of 
differentiation, when cardiac progenitor specification takes place along this differentiation 
protocol, it is evident that CCBE1 is downregulated in the BRA KD line. Given that BRA 
expression level is relatively low at this time point, this result could be indirectly related with 
the low BRA expression levels at 36h, which could prevent BRA downstream genes from being 
activated that in turn activate CCBE1. Alternatively, the lack of BRA could directly prevent the 
induction of CCBE1 in cardiac progenitor cells by not being present and thus not binding to 
activate CCBE1. 
With regard to the pluripotent state, CCBE1 mRNA expression levels were higher both in BRA 
and in ISL1 KD lines. There is a report showing that BRA has a role in pluripotency by 
upregulating the expression of NANOG (Belmonte et al., 2006). Thus, with lower levels of BRA 
expression, those cells would easily differentiate, which could explain the CCBE1 higher 
expression level. However, as for the ISL1 KD clone, CCBE1 result remains unenlightened. Thus, 
a more  efficient ISL1 KD line need to be generated, to present lower expression levels at day 
three of differentiation and subsequently the CCBE1 data from this clone would be more 
consistent and reliable.   
As for the ISL1 KD line results, they reveal that CCBE1 mRNA levels are not significantly 
affected during cardiac differentiation. This result suggests that ISL1 does not activate CCBE1 
despite there being binding of ISL1 to CCBE1 gene. As such, it appears that neither ISL1 nor 
CCBE1 have acted as activators of one another. In fact, although mCcbe1 transcripts are 
present in both the FHF and the SHF, higher levels of CCBE1 are expressed by the FHF 
progenitors, which are ISL1low, in contrast with the SHF, characterized by high levels of ISL1 
transcripts (Facucho-Oliveira et al., 2011).  
All these experiments overlooking CCBE1 characterization, regulation and function in hESCs, 
confirm that CCBE1 plays not only an important role in cardiac specification but also in 
pluripotency maintenance. HESCs hold huge promise in modern regenerative medicine and as 
a model for studying early heart development.  
Concluding, understanding heart development in molecular and cellular terms might have an 
impact on clinical management of congenital malformations and might help to efficiently 
generate stem cell-derived myocardial tissue for substitutive therapies. Here a novel gene, 
CCBE1, involved in cardiac progenitor specification was studied and showed to be an 
important early mesoderm and cardiac mesoderm regulator.  
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5. FUTURE PERSPECTIVES 
 
With this study many questions about CCBE1 expression in hES cells were enlightened, 
however many others remain up in the air. 
To complement the KD data and elucidate CCBE1 function both in pluripotency and along 
cardiac differentiation, three further studies should be performed: the study of the CCBE1 
knock out, a CCBE1 over expression study and the analysis of CCBE1 signalling. For the first two 
studies vectors will need to be generated in order to disrupt CCBE1 expression, both of them 
should be inducible to distinguish between CCBE1 function in pluripotency and in cardiac 
progenitors. As for the third study, a purified recombinant protein will need to be generated 
and added to the differentiation medium. Moreover, it would also be beneficial to perform an 
experiment in which the knock down would be inducible, so that at different stages of the 
differentiation process CCBE1 expression could be switched off, to exclude any influence of 
instability from pluripotent cells. 
Another important approach to study CCBE1 function in pluripotency is to stimulate 
differentiation in additional hESCs lineages with wild type and modified CCBE1 expression, 
followed by characterization of these. 
An important topic that was not addresses in this work was the recognition of the specific 
receptor and signalling pathway of this growth factor. It is paramount to identify the receptor 
(or receptors, once it has several domains) to which CCBE1 bind, the proteins involved in the 
signalling cascade(s) induced by CCBE1 and the target genes which these signalling cascade  
induce and/or repress, to further understand and mechanism of CCBE1 function.  
Regarding CCBE1 regulation it was proposed that BRA together with NANOG or ISL1 has an 
induction action. To be sure BRA forms a dimer with NANOG or ISL1, an immunoprecipitation 
assay needs to be performed. Subsequently, it needs to be proven that these dimers have the 
capacity to activate the CCBE1 promoter, even if preliminary ISL1 KD data do not support part 
of this hypothesis. Thus, other transcription factors should be tested, taking into account ChIP-
seq data bases.  
Finally, an attractive result is that BRA changes its position between 3 prime and middle 
regions as cells differentiate, so it would be interesting to perform Chromatin 
immunoprecipitation for time points between D0 and 60h hours and before 60h. 
 
 
 
 
 
 
44 
 
6. REFERENCES 
 
Alders, M. et al. Mutations in CCBE1 cause generalized lymph vessel dysplasia in humans. Nat 
Genet 12, 1272-1275 (2009). 
Barton, C. Collagen and calcium-binding EGF domains 1 is frequently inactivated in ovarian 
cancer by aberrant promoter hypermethylation and modulates cell migration and survival. 
British Journal of Cancer 102, 87 – 96 (2010). 
Beckingham, K. et al. Calcium-binding proteins and development. BioMetals 11, 359-373 
(1998). 
Belmonte, JC. et al. Maintenance of embryonic stem cell pluripotency by Nanog-mediated 
reversal of mesoderm specification. Nature Clin Pract Cardiovasc Med. 3, S114-S122 (2006). 
Bento, M. et al. Identification of differentially expressed genes in the heart precursor cells of 
the chick embryo. Gene Expr Patterns 11, 437-447 (2011). 
Bernardo, A.S. et al. BRACHYURY and CDX2 mediate BMP-induced differentiation of human 
and mouse pluripotent stem cells into embryonic and extraembryonic lineages. Cell Stem Cell 
9, 144–155 (2011). 
Bondue, A. et al. Mesp1 : A Key Regulator of Cardiovascular Lineage Commitment. Circ Res. 
107(12):1414-1427 (2010). 
Bos, F.L., et al. CCBE1 is essential for mammalian lymphatic vascular development and 
enhances the lymphangiogenic effect of vascular endothelial growth factor-C in vivo. Circ Res 
109, 486-491 (2011). 
Boullin, J. and Morgan, J. et al. The development of cardiac rhythm. Heart 91(7), 874-875 
(2005). 
Boyer, L.A. et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 
122, 947–956 (2005).  
Brand, T. Heart development: molecular insights into cardiac speciﬁcation and early 
morphogenesis. Developmental Biology 258, 1–19 (2003). 
Buckingham, M. et al. Building the mammalian heart from two sources of myocardial cells. 
Nature Rev. Genet. 6(11), 826-835 (2005). 
Burdon, T. et al. Signalling, cell cycle and pluripotency in embryonic stem cells. Trends in Cell 
Biol. 12 (9), 432-438 (2002). 
Chambers and Tomlinson. The transcriptional foundation of pluripotency. Development 136, 
2311-2322 (2009). 
Cheung, C. et al.  Generation of human vascular smooth muscle subtypes provides insight into 
embryological origin–dependent disease susceptibility. Nature Biotechnology 30, 165-173 
(2012). 
Connell, F. et al. Linkage and sequence analysis indicate that CCBE1 is mutated in recessively 
inherited generalized lymphatic dysplasia. Hum Genet 127, 231-241 (2010). 
45 
 
Facucho-Oliveira, J. et al. Ccbe1 expression marks the cardiac and lymphatic progenitor 
lineages during early stages of mouse development. Int J Dev Biol 55, 1007-1014 (2011). 
Geens, M. et al. Human embryonic stem cell lines derived from single blastomeres of two 4-
cell stage embryos. Hum Reprod. 24(11), 2709-2717 (2009). 
Gilbert, S. Developmental Biology, 7th Edition, chap. 6, 11, 15. Sinauer Associates, Inc., (2003). 
Gschwind, A. Cell communication networks: epidermal growth factor receptor transactivation 
as the paradigm for interreceptor signal transmission. Oncogene 20, 1594 – 1600 (2001). 
Harvey, R. Patterning the vertebrate heart. Nature Rev. Genet. 3(7), 544-556 (2002). 
Jackson, K. et al. Regeneration of ischemic cardiac muscle and vascular endothelium by adult 
stem cells. J Clin Invest. 107(11), 1395–1402 (2001). 
Jaenisch, R. and Young, R. Stem Cells, the Molecular Circuitry of Pluripotency and Nuclear 
Reprogramming. Cell 132, 567–582 (2008). 
Jura, M. Catalytic control in the EGF Receptor and its connection to general kinase regulatory 
mechanisms. Mol Cell. 42(1), 9–22 (2011). 
Kehat, I. et al. Human embryonic stem cells can differentiate into myocytes with structural and 
functional properties of cardiomyocytes. J Clin Invest.108(3), 407-414 (2001). 
Keller, R. Cell migration during gastrulation. Curr Opin in Cell Biol 17, 533–541 (2005). 
Kouskoff et al. Sequential development of hematopoietic and cardiac mesoderm during 
embryonic stem cell differentiation. PNAS 102 (37), 13170–13175 (2005).   
Lawson et al. Clonal analysis of epiblast fate during germ layer formation in the mouse 
embryo. Development 113, 891-911 (1991). 
Lee, K.F. et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. 
Nature. 378(6555), 394-8 (1995). 
Livak et al. Analysis of Relative Gene Expression Data Using RealTime Quantitative PCR and the 
2-ΔΔCT Method. Methods 25(4), 402-408 (2001). 
McLean, A.B., et al. Activin A efficiently specifies definitive endoderm from human embryonic 
stem cells only when phosphatidylinositol 3-kinase signaling is suppressed. Stem Cells 25, 29-
38 (2007). 
Musunuru et al. Stem Cell Models of Cardiac Development and Disease. Annu. Rev. Cell Dev. 
Biol. 26, 667-687 (2010). 
Nanba, D. et al. Loss of HB-EGF in smooth muscle or endothelial cell lineages causes heart 
malformation. Biochem Biophys Res Commun. 350(2), 315-321 (2006). 
Nichols, J. Introducing embryonic stem cells. Curr Biol. 11(13), R503-R505 (2001). 
Nyati, M. et al. Integration of EGFR inhibitors with radiochemotherapy. Nature Reviews Cancer 
6, 876–885 (2006). 
Ohta, S. et al. The cessation of gastrulation. Cell Adhesion & Migration 4(3), 440-446 (2010). 
46 
 
Redkar, A. et al. Fate map of early avian cardiac progenitor cells. Development 128, 2269–2279 
(2001). 
Schultheiss et al. A role for bone morphogenetic proteins in the induction of cardiac 
myogenesis. Genes Dev. 11, 451-462 (1997). 
Schultheiss and Alsan. Regulation of avian cardiogenesis by Fgf8 signaling. Development 129, 
1935-1943 (2002). 
Thomson, J. A. et al. Embryonic stem cell lines derived from human blastocysts. Science 282, 
1145–1147 (1998). 
Tavares, A.T. et al. Cerberus is a feedback inhibitor of Nodal asymmetric signaling in the chick 
embryo. Development 134 (11), 2051–2060 (2007). 
Tonegawa, A. et al. Mesodermal subdivision along the mediolateral axis in chicken controlled 
by different concentrations of BMP-4. Development 124(10), 1975-1984 (1997). 
Vallier, L. et al. Activin/Nodal and FGF pathways cooperate to maintain pluripotency of human 
embryonic stem cells. J. Cell Sci. 118, 4495–4509 (2005). 
Vincent, D. and Buckingham, E. How to make a heart: the origin and regulation of cardiac 
progenitor cells. Curr Top Dev Biol. 90, 1-41 (2010). 
Wang, Z. et al. Distinct Lineage Specification Roles for NANOG, OCT4, and SOX2 in Human 
Embryonic Stem Cells. Cell Stem Cell 10, 440–454 (2012). 
Wells, A. EGF receptor. Inter J of Biochem & Cell Biol 31, 637-643 (1999). 
Wolpert, L. Principles of Development, 3rd edition, chap. 3. Oxford University Press (2007). 
Wouters, M. et al. Evolution of distinct EGF domains with specific functions. Protein Science 14, 
1091–1103 (2005). 
Wray, J. et al. The ground state of pluripotency. Biochem Soc Trans 38(4), 1027-1032 (2010). 
Yáñez, M. et al. Calcium binding proteins. Adv Exp Med Biol. 740, 461-82 (2012). 
Yang, X. et al. Cell Movement Patterns during Gastrulation in the Chick Are Controlled by 
Positive and Negative Chemotaxis Mediated by FGF4 and FGF8. Developmental Cell 3, 425–437 
(2002). 
Yu P., et al. FGF2 sustains NANOG and switches the outcome of BMP4-induced human 
embryonic stem cell differentiation. Cell Stem Cell 8(3):326-334 (2011). 
Zhang, X. et al. Derivation of human embryonic stem cells from developing and arrested 
embryos. Stem Cells. 24(12), 2669-2676. (2006). 
http://www.stanford.edu/class/history13/earlysciencelab/body/heartpages/heart.html (15-07-
2012). 
http://www.ensembl.org/Homo_sapiens/Transcript/Summary?db=core;g=ENSG00000183287;
r=18:57102442-57364574;t=ENST00000439986 (08/06/2012). 
http://www.who.int/mediacentre/factsheets/fs310/en/index.html (01/09/2012). 
